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by	 memory	 loss	 and	 cognitive	 decline	 that	 severely	 affect	 activities	 of	 daily	 living.	
Neuropathologically,	the	disease	is	characterised	by	two	major	proteinopathies,	extracellular	




in	 the	predementia	stages	of	AD	pathophysiology.	The	aim	of	 this	PhD	 is	 to	 investigate	the	
utility	of	advanced	Magnetic	Resonance	Imaging	(MRI)	techniques	for	the	earlier	detection	of	
AD	 across	 different	 biomarker	 endophenotypes	 of	 pathogenesis.	 These	 PhD	 investigations	
consist	of:	1)	A	comparison	of	an	automated	hippocampal	subfield	technique	over	standard	
hippocampal	 volumetry	 for	 AD	 classification	 and	 Mild	 Cognitive	 Impairment	 (MCI)	 to	 AD	
conversion	prediction,	2)	A	neuroimaging-proteomic	study	for	testing	the	prognostic	ability	of	
novel	cerebrospinal	fluid	(CSF)	proteins	in	combination	with	structural	MRI	measurements	for	
AD	 classification	 and	MCI	 to	 AD	 conversion	 prediction,	 3)	 An	 extensive	multi-cohort	 study	
testing	 the	 neuroanatomic	 relationship	 between	 Apolipoprotein	 E	 (APOE),	 hippocampal	
volume,	and	Aβ	deposition	across	 the	AD	spectrum,	4)	A	study	of	 the	neurodevelopmental	
effect	of	APOE	polymorphisms	on	brain	structure	in	adolescence	and	5)	A	neuroimaging	study	
testing	 the	 utility	 of	 resting-state	 functional	MRI	 (rsfMRI)	 for	 characterising	 the	 functional	
systems-level	 pathology	 of	 intrinsic	 networks	 anchored	 in	 the	 highly	 metabolically	 active	
posteromedial	cortex.	In	conclusion,	in	this	thesis	I	provide	evidence	to	show	the	diagnostic	
efficacy	 of	 structural	 MRI	 techniques	 across	 different	 biomarker	 interactions	 for	 disease	
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Figure	 4:	 Differences	 in	 brain	 atrophy,	 metabolism,	 and	 Aβ	 deposition	 in	 the	 AD	
pathophysiological	spectrum	.............................................................................................	40	
	
CHAPTER	 2:	 AUTOMATED	 HIPPOCAMPAL	 SUBFIELD	 MEASURES	 AS	 PREDICTORS	 OF	
CONVERSION	FROM	MILD	COGNITIVE	IMPAIRMENT	TO	ALZHEIMER’S	DISEASE	
Figure	1:	(A)	Coronal	and	(B)	Sagittal	views	of	the	Hippocampus	.............................................	90	






































































decades	 prior	 to	 the	 clinical	manifestation	of	AD.	As	 a	 result,	 successful	 disease	modifying	
therapies	would	benefit	from	an	accurate	earlier	diagnosis	of	the	disease,	particularly	at	a	stage	










The	 clinical	 features	 of	 AD	 are	 an	 observable	 phenotype	 of	 the	 cumulative	 burden	 from	
multiple	 pathological	 insults	 to	 the	 brain.	 These	 pathologies	 are	 defined	 by	 the	 combined	
presence	of	two	predominant	classes	of	abnormal	hallmarks,	extracellular	senile	plaques,	and	
intraneuronal	neurofibrillary	tangles	(NFTs),	both	of	which	comprise	highly	insoluble,	densely	





Recent	 studies	 have	 suggested	 that	 it	may	 be	 the	 lack	 of	 Aβ	 clearance	 rather	 than	 excess	
accumulation	 that	 is	 involved	 in	 the	 pathogenesis	 of	 AD	 [5,6].	 Aβ	 peptides	 are	 proteolytic	
fragments	 of	 the	 transmembrane	 enriched	 amyloid	 precursor	 protein	 (APP),	 which	 when	
cleaved	by	secretases	through	a	series	of	amyloidogenic	pathways	produces	a	42-amino	acid	
peptide	(Aβ(1-42)).	This	particular	peptide	has	a	high	propensity	for	aggregation	under	certain	






On	 the	 other	 hand,	 NFTs	 result	 from	 hyperphosphorylated	 microtubule-associated	 tau	
proteins.	 This	 process	 occurs	 when	 hyperphosphorylated	 tau	 undergoes	 a	 conformational	
change	preventing	normal	binding	to	microtubules.	This	results	in	the	impairment	of	axonal	











histology	 suggests	 that	 abnormal	 Aβ	 initiates	 the	 pathological	 cascade	 resulting	 in	 the	
formation	of	NFTs	that	mediate	synaptic	dysfunction	and	neuronal	death	[14].	However,	some	


























on	 Aging-Alzheimer’s	 Association	 (NIA-AA)	 [19]	 and	 National	 Institute	 of	 Neurological	
Disorders	 and	 Stroke-Alzheimer	 Disease	 and	 Related	 Disorders	 (NINCDS-ADRDA)	 [18].	 The	
diagnosis	of	AD	 is	made	based	on	the	clinical	 features	of	 the	disease,	with	a	presence	of	a	
memory	disorder	and	an	 impairment	 in	at	 least	one	other	cognitive	domain,	both	of	which	
interfere	with	social	function	or	activities	of	daily	living.		
	
In	 an	 attempt	 to	 further	 elucidate	 the	 clinical	 phenotype	 of	 the	 AD	 syndrome,	 a	 clinical	




criteria.	 	 Recently,	 revised	 core	 clinical	 criteria	 for	 the	 diagnosis	 of	 AD	 due	 to	 MCI	 were	
published	 for	 application	 in	 clinical	 and	 research	 settings	 [22].	 These	 revised	 criteria	 now	






This	 figure	 shows	 a	 theoretical	 timeline	 for	 the	 progression	 of	 AD-related	
neuropathology	 and	 clinical	 changes,	 with	 changes	 in	 amyloid	 and	 tau	 pathology	
occurring	years	before	the	onset	of	AD.	The	grey,	blue,	and	red	shaded	bars	reflect	time	




been	supported	by	 the	emergence	of	biomarker	discovery	 for	 testing	sensitive	and	specific	















Biomarkers	 Definition	 Working	 Group	 in	 1998,	 a	 biomarker	 is	 evidence	 of	 any	 normal	
biological	 processes,	 pathological	 processes,	 or	 pharmacological	 responses	 to	 therapeutic	
intervention	that	can	be	reproduced	and	measured	accurately	[26,27].	In	order	to	identify	a	
good	biomarker	with	diagnostic	utility	it	must	be	sensitive,	specific,	and	easy	to	administer	to	













AD	 pathology.	 Biomarkers	 are	 also	 important	 for	 clinical	 trials	 of	 novel	 pharmaceutical	
interventions	to	enrich	samples	with	individuals	most	likely	to	progress	to	an	AD	diagnosis	and	
monitor	the	outcome	of	therapeutic	interventions.	As	a	result,	multi-centre	consortium	studies	
have	 been	 designed	 to	 longitudinally	 evaluate	 the	 role	 of	 neuroimaging,	 CSF,	 and	 blood	
biomarkers,	 neuropsychological,	 clinical,	 and	 genetic	 risk	 factors,	 in	 detecting	 AD	
pathophysiological	changes,	especially	during	the	prodromal	stages	of	development,	to	track	
disease	 progression	 and	 predict	 future	 decline.	 The	 US-based	 Alzheimer’s	 Disease	
Neuroimaging	Initiative	(ADNI),	established	in	2004,	is	primarily	intended	to	help	inform	the	



























A	 theoretical	 representation	 of	 the	 biomarker	 trajectories	 during	
different	stages	of	AD	pathogenesis.	This	illustration	demonstrates	that	
some	 markers	 may	 be	 more	 useful	 for	 detecting	 the	 pathological	
changes	 in	AD	during	different	 stages	of	development.	 For	 instance,	
some	markers	may	be	useful	for	early	diagnosis,	whereas	others	may	
have	 more	 prognostic	 potential	 in	 tracking	 disease	 progression.	
Amyloid	 markers	 (CSF	 Aβ(1-42)	 and	 Aβ	 PET)	 represent	 the	 earliest	
detectable	 changes	 in	 AD,	 but	 begin	 to	 plateau	 at	 the	 MCI	 stage.	
Functional	 and	 metabolic	 markers	 (FDG-PET	 measurements	 of	
hypometabolism	 and	 functional	MRI	methods)	 become	 abnormal	 at	
the	MCI	stage	and	progressively	change	well	into	the	dementia	stage.	
Changes	 on	 structural	MRI	 become	 abnormal	 during	 the	MCI	 stage,	
often	following	a	temporal	pattern	of	changes	that	correspond	to	tau	
pathology	in	the	brain.		Most	extensively	used	measurements	included	
hippocampal	 and	 entorhinal	 volume,	 as	 well	 as	 measurements	 of	
whole-brain	 atrophy.	 Abbreviations:	 AD,	 Alzheimer’s	 Disease;	 MCI,	
Mild	 Cognitive	 Impairment;	 NINCDS-ADRDA,	 National	 Institute	 of	
Neurological	 and	 Communicative	 Disorders	 and	 Stroke-Alzheimer’s	





Structural	MRI	 as	 a	measure	of	 atrophy	 is	 regarded	as	 a	 valid	marker	of	disease	 state	 and	
progression.	 It	 is	also	a	widely	established	method	for	quantifying	regional	and	global	brain	
volumes	in-vivo.	Previous	studies	have	shown	that	the	topography	of	tissue	loss,	detected	both	











Historically,	 manual	 delineation	 methods	 were	 implemented	 to	 extract	 volumetric	 and	
morphometric	characteristics	of	atrophy,	including	manual	tracings	of	region-of-interest	that	
typically	 measure	 hippocampal	 and	 entorhinal	 volumes	 [42,43].	 These	 manual	 volumetric	
methods	have	achieved	promising	accuracies	for	distinguishing	patients	with	AD	from	normal	
healthy	 individuals	[44],	and	predicting	 incipient	AD	in	MCI	patients	that	go	on	to	receive	a	






to	 avoid	 biases.	 Consequently,	 sophisticated	 computational	 algorithms	 that	 enable	 the	
automated	segmentation	of	complex	structures	such	as	the	hippocampus	are	highly	desirable	






volumetric	estimates	of	 the	hippocampus	are	highly	 correlated	and	exhibit	 greater	 volume	
overlap.	 More	 recent	 work	 has	 compared	 two	 popular	 and	more	 widely	 used	 automated	
software	tools	such	as	FreeSurfer	and	FSL	FIRST	to	assess	the	accuracy	of	their	segmentation	
algorithms	 [48,49].	 Morey	 and	 colleagues	 [50]	 compared	 manual	 tracings	 to	 automated	
segmentations	of	the	hippocampus	from	FreeSurfer	and	FSL	and	concluded	that	FreeSurfer	
was	superior	to	FSL	FIRST	for	all	aspects	of	the	objective	measured	used.	Recent	work	has	since	
corroborated	 this	 evidence	 by	 demonstrating	 FreeSurfer	 as	 the	 superior	 technique	 for	








over	 time	 as	 the	 disease	 progresses.	 Capturing	 these	 dynamic	 spatio-temporal	 patterns	 of	
cortical	 change	 often	 require	 high-dimensional	 image	 warping	 and	 sophisticated	
computational	tools	to	quantify	the	regional	distribution	of	brain	tissue.	In	order	to	achieve	
this,	 studies	 have	 used	 advanced	 pattern	 classification	 methods	 and	 machine	 learning	
algorithms	to	detect	patterns	of	cortical	change	for	disease	classification	and	prediction	[53].	




known	 as	 the	 SPARE-AD	 index	 (Spatial	 Pattern	 of	 Abnormality	 for	 Recognition	 of	 Early	
Alzheimer’s	Disease),	that	generates	a	quantitative	control-like	phenotype	(negative	values)	
and	AD-like	phenotype	(positive	values)	of	spatial	atrophy	patterns	to	detect	incipient	stages	
of	 AD	 in	 normal	 older	 adults	 [55].	 Sophisticated	 multimodal	 pattern	 classifiers	 combining	
different	modalities	of	biomarkers	have	also	shown	promise	for	distinguishing	between	MCI	
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is	 a	 sensitive	 neuroimaging	 technique	 that	 measures	 the	 quantification	 of	 radiological	
compounds	in-vivo,	allowing	the	non-invasive	assessment	of	molecular	processes	at	different	
sites	 of	 action.	 Several	 radiological-contrast	 compounds,	 known	 as	 PET	 ligands	 have	 been	
developed	to	evaluate	different	metabolic	and	neurochemical	processes	 in	the	brain.	 In	AD	
research,	 two	 types	of	PET	 ligands	are	primarily	utilised:	1)	 [18F]	 fluorodeoxyglucose	 (FDG),	
which	measures	the	functional	neuronal	metabolism	of	the	brain	[57,58]	and	2)	ligands	for	the	

















the	 utility	 of	 FDG-PET	 in	 the	 differential	 diagnosis	 of	 major	 neurodegenerative	 dementia	
disorders.		
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[68].	 Longitudinal	PiB	 studies	have	since	 shown	 that	 small,	 albeit	 significant	changes	 in	 the	
accumulation	of	Aβ	plaques	can	be	quantified	and	represent	changes	across	the	different	AD	




have	 since	 been	 corroborated	 by	 a	 wave	 of	 second	 generation	 PET	 ligands,	 namely	 [18F]	
Flutemetamol,	and	[18F]	Florbetapir,	which	were	designed	to	circumvent	the	radioactive	decay	
half-life	 limitations	 of	 PiB,	 and	 ensure	 that	 Aβ	 PET	 imaging	was	more	widely	 available	 for	
routine	clinical	use	[72].		
	
The	 success	of	Aβ	PET	 imaging	has	 spurred	efforts	worldwide	 to	develop	 selective	 tau	PET	
radiological	 tracers	 to	 enable	 the	 in-vivo	 assessment	 of	 regional	 tau	 burden.	 The	
hyperphosphorylated	state	of	tau	is	complex,	particularly	since	there	are	six	different	isoforms	
of	tau	in	the	human	tissue.	Consequently,	the	development	of	a	selective	tau	PET	tracer	should	
provide	 the	 ability	 to	 evaluate	 the	 severity	 of	 tau	 pathology	 during	 different	 stages	 of	 AD	
pathogenesis.	Currently,	at	least	7	different	tau	PET	tracers	have	been	developed	and	used	in	


































the	 injection	 of	 a	 contrast	 agent,	 and	 thus	 can	 be	 repeated	 several	 times	 in	 studies	 of	 a	






Blood	 oxygen	 level	 dependent	 (BOLD)	 fMRI	 represents	 an	 indirect	 measure	 of	 neuronal	
activity,	thought	to	reflect	the	integrated	synaptic	activity	of	neurons	through	changes	in	the	
magnetic	 resonance	 signal	 due	 to	 changes	 in	 blood	 flow,	 blood	 volume,	 and	 blood	
oxyhaemoglobin/deoxyhaemoglobin	 ratio,	 inferred	 from	 measuring	 the	 BOLD	 fMRI	 signal	
[81,82].	 In	 particular,	 rsfMRI	 techniques	 at	 their	 most	 rudimentary	 level,	 represent	 the	
measure	of	correlated	signal	between	two	or	more	spatially	distinct	regions	across	time.	Since	
the	 discovery	 of	 low-frequency	 fluctuations	 (0.1	 to	 0.01	 Hz)	 in	 the	 BOLD	 signal,	 and	 its	
specificity	 to	 grey	 matter	 [83],	 studies	 have	 revealed	 a	 number	 of	 brain	 networks	 that	
















with	 another	 pre-defined	 seed	 region	 to	measure	 seed-to-seed	 connectivity.	On	 the	 other	
hand,	ICA	is	a	multivariate	analysis	technique	that	can	be	used	to	extract	a	variety	of	distinct	
structured	signals	that	are	statistically	independent.	ICA	methods	do	not	necessitate	the	priori	
definition	of	 regions	 from	which	BOLD	 fluctuations	are	 to	be	extracted,	but	 rather	extracts	






the	 optimal	 source	 for	 obtaining	 sensitive	 and	 specific	 biomarkers	 that	 can	 reflect	 the	
underlying	biochemical	perturbations	in	the	AD	brain.	Three	major	protein	constituents	of	AD	




changes	 in	 inflammation,	microglial	activity,	and	synaptic	 function	are	also	being	sought	 to	
characterise	an	accurate	peripheral	signature	for	improving	the	prognostic	ability	of	existing	
CSF	biomarkers.	 The	main	problem	with	CSF	biomarkers	 is	 that	 they	 are	hampered	by	 the	
invasive	lumbar	puncture	procedure	required	for	CSF	collection.		Therefore,	efforts	are	being	
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senile	 plaques,	 hence	 the	 retention	 of	 the	 peptide	 in	 the	 brain	 parenchyma.	 This	massive	
accumulation	of	Aβ	into	pathological	deposits	is	believed	to	reflect	a	~40%	reduction	in	CSF	Aβ	







NFT	 pathology	 in	 the	 brain.	 Tau-neurodegeneration	 is	 concomitant	 with	 normal	 healthy	



































have	 met	 with	 little	 success.	 The	 future	 development	 of	 harmonized	 protocols	 for	 the	
collection,	 storage,	 and	 subsequent	 analytical	 procedures	 of	 blood	 biomarkers	would	 help	













structure	of	each	APOE	 isoform,	and	hence	 influence	their	activity	 in	 lipid	homeostasis	and	
trafficking.		
	
The	 APOE	 e4	 isoform	 is	 dramatically	 increased	 in	 patients	 with	 AD,	 with	 approximate	













in	 the	 Default-Mode	 Network	 (DMN)	 [106,107].	 Accumulating	 evidence	 also	 suggests	 that	
APOE	e4	carriers	exhibit	lower	cerebral	glucose	metabolism	than	non-carriers,	both	at	rest	and	
during	cognitively-demanding	tasks	 [57].	These	studies	 illustrate	 that	APOE	e4	 is	associated	










e2	 in	 staving	off	 AD	neuropathology	 are	 less	 consistent	 [108,110].	 These	 studies	 are	 often	
limited	by	 their	sample	size	due	to	 the	 inherent	 low	allelic	 frequency	of	APOE	e2,	and	as	a	
result,	possess	insufficient	statistical	power	to	test	its	function	and	biological	mechanisms.		
	
Although	 APOE	 e4	 is	 the	 most	 significant	 genetic	 variant	 associated	 with	 AD,	 it	 does	 not	
account	for	all	AD	heritability.	In	early-onset	form	of	AD,	rare	autosomal	dominant	mutations	
in	amyloid	precursor	protein	(APP),	a	constituent	of	Aβ	peptides,	and	the	presenilins	genes	
(PSEN1	and	PSEN2)	are	commonly	 implicated	 in	 its	development.	Alternative	 to	candidate-
gene	approaches,	genome-wide	association	(GWA)	studies	have	identified	rare	homozygous	
loss-of-function	mutations	 in	TREM2,	a	gene	that	encodes	triggering	receptor	expressed	on	
myeloid	 cells	 2	 protein	 [111,112].	 This	 rare	 variant	 of	 TREM2,	which	 results	 in	 a	missense	


















Structural	 MRI	 remains	 the	 most	 extensively	 applied	 MRI	 technique	 in	 AD	 research	 for	
estimating	brain	atrophy	as	a	concomitant	of	progressive	tau	neurodegeneration.	AD	patients	









possession	of	APOE	e4	 in	a	dose-dependent	 fashion	 [122],	as	well	as	 the	 rates	of	cognitive	
decline	[33].		
	
Since	 the	 spatio-temporal	 patterns	of	 atrophy	 in	AD	 is	 complex,	 and	often	associated	with	
concurrent	neurodegeneration	in	normal	ageing,	advanced	pattern	analysis	techniques	have	
been	developed	for	better	characterising	AD-related	atrophy	[123–125].	Several	studies	have	









































AD.	Numerous	 studies	 have	 reported	 reduced	 cerebral	 glucose	metabolism	 in	 AD	 patients	
relative	 to	 healthy	 controls,	 especially	 in	 the	 temporoparietal	 cortex,	 posterior	 cingulate	
cortex,	parietal	lobe,	and	MTL,	including	the	hippocampus	(Figure	1.4b).	Furthermore,	these	






neuroimaging	 techniques	 and	 fluid	 marker	 measurements	 for	 accurately	 detecting	 AD	
[39,131].		
	
PET	measurements	 for	 detecting	 fibrillar	 Aβ	 plaques	 in	 the	 brain	 now	developed	 almost	 a	
decade	ago,	are	having		a	profound	impact	on	the	study	of	AD	pathogenesis,	and	evaluation	of	
Aβ-modifying	 therapies.	 Several	 validated	Aβ	PET	 radioligands,	 have	 consistently	 shown	an	
increased	uptake	and	binding	of	amyloid	tracers,	most	commonly	with	PiB,	to	brain	regions	
known	 to	 reflect	 abnormal	 Aβ	 levels	 in	 the	 AD	 brain,	 including	 frontal,	 parietal,	 posterior	
cingulate,	and	precuneal	regions	[59,61]	(Figure	1.4c).	Recent	work	has	shown	that	across	over	
15	 clinical	 studies	 of	 11[C]	 PiB-PET,	 almost	 96%	 of	 AD	 patients	 were	 categorised	 as	 “Aβ-
positive”[132].	However,	longitudinal	PiB-PET	studies	report	that	AD	patients	exhibit	minimal	
increases	in	Aβ	accumulation	over	1-2	years	[133].	This	has	led	researchers	to	conclude	that	








than	 structural	 MRI	 measurements	 include	 diffusion	 imaging	 for	 assessing	 brain	
microstructure,	and	rsfMRI	for	measuring	functional	connectivity	at	rest.	New	initiatives	such	
as	the	Human	Connectome	Project	(HCP)	[135]	have	begun	to	construct	a	detailed	map	of	the	











between	 patients	 and	 healthy	 controls	 [136].	 Despite	 the	 disparity	 in	 findings,	 region-of-




changes	 involved	 in	 AD.	 These	 studies	 have	 generally	 reported	 widespread	 tensor	
abnormalities	 in	 parietal,	 temporal	 and	 frontal	 WM,	 and	 inter-hemispheric	 connections	
through	the	corpus	callosum	[139,140].	Overall,	studies	have	highlighted	the	 importance	of	
the	key	limbic	tracts,	such	as	the	fornix,	and	regions	including	the	cingulum	bundle	and	the	
corpus	 callosum	 as	 being	 vulnerable	 to	 AD	 pathogenesis.	 This	 suggests	 that	 tensor	
abnormalities	in	AD	are	concentrated	to	posterior	regions	that	support	memory	function.	This	
further	lends	support	to	the	theory	of	retrogenesis	that	posits	the	high	vulnerability	of	later-
myelinating	 regions	 to	 degeneration	 and	 the	 relative	 sparing	 of	 early-myelinating	 regions	
[141].	Advances	in	optimising	the	acquisition	protocol,	tensor	reconstruction	routines	and	
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BOLD	 signal	 to	assess	 functional	 connectivity	differences	between	AD	patients	 and	healthy	
controls	at	rest.	The	majority	of	earlier	fMRI	studies	in	AD	had	focused	primarily	on	the	pattern	
of	activation	in	the	hippocampus	and	surrounding	MTL	regions	using	explicit	tasks	of	episodic	
and	 working	memory.	 These	 studies	 have	 since	 reported	 a	 consistent	 deactivation	 of	 the	
hippocampal	 formation	 during	 the	 encoding	 of	 new	 information	 in	 patients	 with	 AD,	
suggesting	 these	 networks	 functionally	 succumb	 to	 a	 breakdown	 in	 memory	 processing.	
However,	anatomical	 lesion	studies	and	subsequent	fMRI	studies	have	shown	that	memory	
function	 is	 subserved	 by	 a	 heteromodal	 network	 of	 brain	 regions	 that	 includes	 the	
hippocampal	 memory	 system,	 and	 a	 set	 of	 other	 cortical	 regions	 such	 as	 the	 precuneus,	
posterior	 cingulate	 cortex,	 lateral	 parietal,	 lateral	 temporal,	 and	medial	 prefrontal	 regions.	
Collectively	termed	the	DMN,	a	region	originally	identified	by	Raichle	and	colleagues	[142],	this	
network	 is	 typically	attenuated	 in	 the	context	of	 task	performance	 [143].	Motivated	by	the	
potential	link	between	DMN	function	and	episodic	memory	impairment	in	AD,	several	studies	
have	investigated	the	functional	connectivity	of	the	DMN	in	AD	patients	and	those	at	risk	of	
developing	 the	 disease[144–146].	 The	most	 consistent	 finding	 across	 previous	 studies	 is	 a	
decrease	 in	 DMN	 functional	 connectivity	 in	 AD	 patients	 compared	 to	 healthy	 controls	
[147,148].	Other	intrinsic	networks,	such	as	the	salience	and	executive	control	networks	which	















Controls	 (HC)	 subjects	 is	 demonstrated	 in	 (a)	 brain	 atrophy,	 measured	
using	 structural	MRI,	 (b)	 glucose	metabolism,	measured	 using	 FDG-PET,	
and	 (c)	 Aβ	 accumulation	measuring	 using	 [11C]	 PiB-PET.	 Relative	 to	 HC,	
patients	with	AD	show	significantly	reduced	brain	grey	matter	(GM)	density	
throughout	 cortical	 and	 subcortical	 regions	 (a;	 AD	 versus	 HC),	 reduced	
glucose	 metabolism	 in	 regions	 of	 the	 medial	 and	 lateral	 parietal	 lobe,	
medial	and	lateral	temporal	lobes,	and	medial	and	lateral	frontal	lobes	(b;	
AD	 versus	 HC),	 as	 well	 as	 increased	 Aβ	 accumulation	 throughout	 the	
cerebral	cortex	(c;	AD	versus	HC).MCI	patients	also	show	similar,	although	
more	focal,	changes	relative	to	HC,	 including	reduced	GM	density	 in	the	
medial	 and	 lateral	 temporal	 lobes	 (a;	MCI	 versus	 HC),	 reduced	 glucose	
metabolism	 in	the	medial	and	 lateral	 temporal	 lobes,	medial	and	 lateral	
parietal	 lobes,	 and	 frontal	 lobe	 (b;	 MCI	 versus	 HC),	 and	 greater	 Aβ	
deposition	in	the	frontal,	parietal,	and	temporal	cortices	(c;	MCI	versus	HC).	
Specifically,	 patients	 with	 AD	 show	 significantly	 more	 GM	 atrophy	 in	
regions	of	the	medial	and	lateral	temporal	lobes	and	parietal	lobes	(a;	AD	
















a	 transitional	 stage	 of	 AD	 pathogenesis,	 with	 an	 intermediate	 severity	 of	 cortical	 atrophy	
between	AD	patients	and	healthy	controls	[157].	Although	the	presence	of	atrophy	in	AD	is	
widespread	throughout	the	neocortex,	amnestic	MCI	is	associated	with	a	more	focal	pattern	
of	 structural	 vulnerability.	 Specifically,	MCI	 patients	 exhibit	 significant	 atrophy	 in	 the	MTL,	








Moreover,	 pattern	 classification	 techniques	 using	 global	 and	 regional	measures	 of	 atrophy	
have	been	able	to	distinguish	MCI	patients	from	normal	healthy	controls,	with	accuracies	of	
~85-89%	 [161].	 Structural	 MRI	 measurements	 have	 also	 shown	 a	 prognostic	 potential	 in	


















is	 also	 found	 to	 predict	 subsequent	 clinical	 conversion	 to	 probable	 AD	 [167,168],	 though	
distinguishing	MCI	converters	 from	non-converters	has	been	 less	 successful	 than	structural	





have	 significantly	 higher	 11[C]	 PiB	 uptake	 compared	 to	 healthy	 controls	 in	 several	 areas,	
especially	 the	 frontal	 cortex,	 posterior	 cingulate,	 parietal	 and	 lateral	 temporal	 cortices,	
putamen,	and	caudate	 [170,171]	 (Figure	1.4c).	Furthermore,	clinical	 follow-up	studies	have	
also	suggested	that	this	pattern	of	high	tracer	uptake	in	MCI	patients	is	predictive	of	future	
clinical	conversion	to	probable	AD	[172].	However,	longitudinal	PET	studies	in	AD	patients	have	











In	 other	 advanced	 imaging	 techniques	 such	 as	 DTI,	 studies	 have	 further	 investigated	 the	
posterior	 circuitry	 (hippocampus,	 parahippocampal	WM,	 posterior	 cingulate,	 and	 cingulum	
bundle)	that	 is	preferentially	affected	 in	AD.	 In	general,	MCI	patients	show	an	 intermediate	
reduction	of	FA	relative	to	healthy	controls	and	AD	patients	in	the	cingulum	bundle,	temporal	







between	 AD	 and	 MCI	 patients	 can	 be	 observed,	 it	 must	 be	 noted	 that	 there	 are	 many	






stages	 of	 AD.	 Studies	 with	 further	 well-characterised	 MCI	 cases	 representative	 of	 its	
heterogeneity	in	the	general	population,	as	well	as	advances	in	DTI	pulse	sequences,	will	help	
improve	 our	 ability	 to	 observe	more	 consistent	 findings	 in	WM	microstructure	 differences	
between	AD	and	MCI	patients.		
	
On	 the	 other	 hand,	 rsfMRI	 studies	 in	 MCI	 patients	 have	 predominantly	 focused	 on	 the	
functional	 connectivity	of	 the	DMN,	as	 this	network	 is	 primarily	 active	during	episodic	 and	
autobiographical	memory	retrieval,	but	shows	a	decrease	in	activity	during	the	performance	
on	cognitive	tasks	that	require	attention.	A	recent	study	by	Binnewijzend	and	colleagues	[175],	
investigated	 the	 regional	 functional	 connectivity	 of	 the	DMN,	 and	 found	 that	MCI	patients	
exhibited	 intermediate	 values	 of	 functional	 connectivity	 between	 AD	 patients	 and	 healthy	





[176,177],	 but	 recent	meta-analyses	 of	 rsfMRI	 studies	 have	 highlighted	 the	 importance	 of	
posteromedial	 regions	 –	 areas	 particularly	 vulnerable	 to	 amyloid	 pathology,	 as	 being	
associated	with	 the	 early	 stages	 of	 the	 disease	 process	 [178,179].	 These	 posterior	midline	
structures	are	also	particularly	vulnerable	to	hypometabolism,	and	previous	work	has	shown	
that	disruption	of	the	PCC	can	lead	to	synaptic	dysfunction	in	the	hippocampus	and	eventual	
cognitive	 decline	 [146].	 Evidence	 has	 suggested	 that	 the	 deterioration	 of	 the	 DMN	 is	






















In	 summary,	 amnestic	 MCI	 patients	 display	 significant	 AD-related	 neuropathology,	 most	
notably	 brain	 atrophy	 in	 MTL	 structures,	 glucose	 hypometabolism	 detected	 by	 FDG-PET,	
amyloid	accumulation,	and	alterations	in	brain	function	at	rest.	These	biomarkers,	in	particular	
	 45	
structural	 MRI,	 often	 indicate	 that	 MCI	 patients	 with	 a	 greater	 AD-like	 neuroimaging	
phenotype	 of	 pathology	 are	 most	 likely	 to	 progress	 to	 the	 disease	 in	 the	 future.	 The	
enhancement	of	other	biomarkers,	such	as	DTI	and	rsfMRI	in	the	future,	may	allow	us	to	detect	









the	 impetus	 to	diagnose	AD	 in	 its	 pre-clinical	 stages	 –	before	 significant	brain	 atrophy	has	
ensued,	has	intensified.	Many	investigators	believe	the	ideal	preventive	treatment	would	be	
prior	 to	 the	emergence	of	 the	MCI	clinical	syndrome	[6].	Recent	advances	 in	neuroimaging	
techniques	now	provide	the	ability	to	detect	evidence	of	AD	pathophysiological	changes	prior	






discussed:	 1)	 cognitively	 normal	 individuals	 reflecting	 abnormal	 levels	 of	 Aβ	 accumulation	
using	PET	Aβ	methods	and	CSF	levels	of	abnormal	Aβ	(1-42),	2)	Individuals	identified	through	a	




cognition	 are	 Aβ	 positive	 [132,183].	 Subsequent	 longitudinal	 studies	 have	 further	
corroborated	 this	 evidence	 and	 shown	 that	 Aβ	 accumulation	 is	 accompanied	 with	 subtle	
declines	in	cognition	[184],	as	well	as	a	greater	risk	of	progression	to	memory	impairment	and	
an	 eventual	 AD	 diagnosis	 [185].	 As	 a	 result,	 these	 subjects	 may	 represent	 a	 pre-clinical	
biomarker	 phenotype	 for	 characterising	 the	 earliest	 pathophysiological	 changes	 associated	
with	the	disease.	Moreover,	recent	work	has	shown	that	emerging	Aβ	pathology	is	associated	
with	 cortical	 atrophy.	 For	 instance,	 some	 studies	 report	 structural	 changes	 in	 stereotypical	
areas	 associated	with	 AD,	 such	 as	 the	 temporal	 cortex	 and	 hippocampal	 structures	 [186],	
whereas	others	report	more	subtle	patterns	of	atrophy	in	regions	less	commonly	associated	
with	 AD,	 such	 as	 the	 frontal	 lobes	 [187].	 The	 disparity	 of	 findings	 from	 imaging	 studies	 of	
preclinical	 patients	 suggests	 that	 the	 temporal	 evolution	 of	 biomarker	 evidence	 is	
heterogeneous	 and	 varies	 on	 an	 individual	 level.	 Since	 the	 formulation	 of	 the	NIA-AA	pre-
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clinical	 staging	 criteria	 for	 AD	 [6],	 a	 two-feature	 biomarker	 classification	 system	 has	 been	











executive	 networks,	which	 are	 known	 to	 share	 a	 reciprocal	 relationship	 in	modulating	 the	
DMN.	Functional	abnormalities	in	preclinical	patients	has	been	further	supported	by	FDG-PET,	
revealing	poor	glucose	metabolism	 in	areas	of	 typically	high	metabolic	activity,	 such	as	 the	
posterior	cingulate	[189].	Although	Aβ	pathology	is	considered	to	increase	the	risk	of	future	
cognitive	 decline	 in	 older	 adults,	 some	 individuals	 are	 known	 to	 exhibit	 normal	 cognitive	




with	 greater	 cognitive	 reserve	 and	 high	 levels	 of	 Aβ	 burden	 had	 lower	 levels	 of	 glucose	
metabolism	in	the	posterior	cingulate,	thus	suggesting	cognitive	reserve	has	a	compensatory	
function	to	sustain	cognitive	ability	in	the	presence	of	AD	pathology	[191].	In	contrast,	others	






of	 cognitive	 decline	 [193],	 suggesting	 that	 the	 genetic	 risk	 of	 APOE	 e4	 is	 associated	 with	
cognitive	 decline	 years	 before	 memory	 impairment	 is	 clinically	 apparent.	 Structural	
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neuroimaging	APOE	studies	have	also	found	that	APOE	e4	carriers	generally	exhibit	higher	rates	
of	 atrophy,	 particularly	 in	 regions	 commonly	 affected	 in	 AD,	 such	 as	 the	 MTL	 and	
temporoparietal	 regions,	 compared	 to	 non-carriers.	 Although	 studies	 do	 report	 brain	
differences	 associated	 with	 APOE	 e4,	 many	 argue	 that	 in	 some	 this	 only	 represents	 non-
pathological	changes	that	are	age-dependent,	as	not	all	APOE	e4	carriers	go	on	to	develop	AD.	




Further	 insights	 into	better	 characterising	 the	pre-clinical	 stages	of	AD	have	 come	 through	
understanding	the	relationship	between	APOE	e4	and	Aβ	metabolism.	APOE	e4	has	been	well	
understood	 to	 influence	 Aβ	 accumulation	 and	 metabolism	 –	 studies	 show	 that	 APOE	 e4	
strongly	 affects	 Aβ	 deposition	 to	 form	 senile	 plaques	 and	 cause	 cerebral	 Aβ	 angiopathy	
[105,195].	 Further	 evidence	 suggests	 that	 APOE	 e4	 combines	 synergistically	 with	 Aβ	






memory	 performance	 in	 APOE	 e4	 carriers	 compared	 to	 non-carriers,	 which	 could	 suggest	
antagonistic	pleiotropy	[197],	whereas	others	report	evidence	of	a	detrimental	effect	of	APOE	
e4	 	 on	 brain	 neurodevelopment	 in	 children	 and	 adolescents	 [198].	 	 While	 studies	 have	
suggested	 that	 Aβ	 deposition	 in	 the	 brain	 begins	many	 decades	 prior	 to	 AD	development,	





An	early	 study	by	 Filippini	 et	 al	 [200],	 showed	 that	APOE	e4	modulates	brain	 function	 and	
activity	 decades	 prior	 to	 any	 clinical	 representation	 of	 neurodegeneration.	 This	 has	 led	
	 49	
researchers	 to	 postulate	 that	 APOE	 e4	 may	 possess	 neurodevelopmental	 changes	 that	
provides	 a	 foothold	 for	 a	 pathological	 cascade	 leading	 to	 subsequent	 AD	 [201].	 Some	
multimodal	imaging	studies	have	since	shown	that	APOE	e4	is	associated	with	alterations	in	
grey	matter	 volume,	white-matter,	 and	brain	 function,	 both	 at	 rest	 and	during	 a	memory-
encoding	paradigm	[201,202].	Despite	this,	it	is	difficult	to	imply	that	these	early	brain	changes	
in	 infancy	 and	 childhood	 are	 solely	 associated	 with	 detrimental	 effects	 of	 APOE	 e4.	
Neurodevelopment	 in	 infancy	 and	 later	 adolescence	 is	 a	 period	 in	 which	 several	
neurobiological	 processes	 may	 influence	 asynchronous	 brain	 maturation,	 thus	 making	 it	
difficult	to	isolate	early	brain	changes	to	the	effects	of	APOE	e4.		
	
Finally,	 cognitively	 normal	 older	 individuals	 who	 have	 significant	 cognitive	 complaints,	 or	
report	subjective	memory	impairment	also	represent	a	subset	of	individuals	with	a	preclinical	
risk	 of	 developing	 AD	 [203].	 Subjective	 memory	 impairment	 is	 defined	 as	 below-normal	
performance	on	memory	tests,	largely	unimpaired	functional	activities	of	daily	living,	and	the	
absence	of	dementia	[204].	Studies	have	reported	that,	compared	to	those	with	no	subjective	
memory	 complaints,	 individuals	with	 subjective	memory	 complaints	 show	medial	 temporal	
lobe	 atrophy	 [205],	 cerebral	 glucose	 hypometabolism	 [39],	 an	 AD-like	 CSF	 biomarker	
phenotype	[206],	and	more	frequent	AD	neuropathology	at	autopsy.	Epidemiological	studies	
have	shown	that	these	individuals	also	have	a	higher	likelihood	of	future	cognitive	decline	and	
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variation	 in	 atrophy,	 hypometabolism,	 and	 Aβ	 deposition,	 as	 well	 as	 the	 low	 interaction	




suggest	 that	 they	 only	 become	 abnormal	 a	 few	 years	 prior	 to	 the	 emergence	 of	 cognitive	




should	 be	 considered	 as	 carrying	 the	 same	 weight	 as	 neuroimaging	 biomarkers	 of	 Aβ	
deposition.	The	problem	faced	by	current	biomarker	discovery	is	that	a	number	of	different	
less	widely	used	brain	 imaging	 techniques	have	been	applied	 to	AD,	but	have	not	been	as	
extensively	 validated	 as	 hippocampal	 volumetry.	 Therefore,	 I	 will	 briefly	 describe	 the	





genetic	 risk	of	developing	AD,	 and	whether	 the	 temporal	 evolution	of	disease	markers	 are	
	 80	
differentially	affected	in	e4	and	e2	allele	carriers.	I	will	describe	the	current	gap	in	the	literature,	





Firstly,	 decline	 in	 hippocampal	 volume	 is	 the	most	 extensively	 reported	MRI	 finding	 in	 AD	
patients	and	MCI	subjects	progressing	to	the	disease.	However,	hippocampal	atrophy	is	not	
specific	 to	 the	 AD	 pathological	 process	 and	 is	 a	 feature	 observed	 in	 other	 psychiatric	 and	
neurological	 diseases.	 Furthermore,	 while	 the	 hippocampus	 is	 often	 mapped	 as	 a	 unitary	
structure,	 it	 is	 in	 fact	 anatomically	 heterogeneous	 and	 divided	 into	 several	 subfields	 with	
distinct	 histological	 characteristics.	 Previous	 studies	 have	 also	 reported	 that	 the	 different	






process	 than	measuring	 global	 hippocampal	 volume	 loss.	 Consequently,	 Chapter	 2	 of	 this	
















advantages	 of	 combining	 structural	 MRI	 measurements	 with	 core	 CSF	 biomarkers	 for	 the	
improved	 detection	 of	 AD	 and	 prediction	 of	 MCI	 patients	 converting	 to	 the	 disease.	
Furthermore,	 studies	 using	 high-dimensional	 pattern	 classification	 techniques	 have	 also	
reported	that	structural	MRI	and	CSF	biomarkers	provide	mutually	complimentary	information	
for	 disease	 classification	 and	 prediction.	 Yet,	 despite	 these	 advantages,	 there	 remains	 a	
substantial	 overlap	 in	 CSF	 biomarker	 values	 between	 AD	 patients	 and	 MCI	 subjects	 and	
demonstrates	a	need	for	better	prognostic	ability.	Neuropathologically,	there	 is	also	a	 large	




However,	 these	 candidates	 have	 not	 yet	 been	 tested	 in	 relation	 with	 structural	 MRI	











the	 neuroanatomic	 effect	 of	 APOE	 e4	 in	 AD	 is	 extensively	 studied,	 the	 mechanisms	 that	
moderate	APOE	e4’s	detrimental	effect	on	the	hippocampus	are	not	well	understood.	Recent	





a	 large	well-characterised	and	extensive	multi-cohort	of	dataset.	This	 included	 imaging	and	






The	 aim	 of	 Chapter	 4	 was	 to	 assess	 the	 neuroanatomic	 effect	 of	 different	 APOE	 gene	
polymorphisms	on	hippocampal	volume	in	the	different	stages	of	AD,	normal	ageing,	and	a	











others	 that	 have	 followed,	 are	 driving	 the	 impetus	 to	 discover	 early	 brain	 differences	
associated	with	a	neurodevelopmental	foothold	of	APOE	e4.	For	this	particular	avenue	of	APOE	
research	current	biomarker	driven	theoretical	frameworks	of	AD	rarely	address	the	prospects	
of	 determining	 AD	 risk	 in	 young	 adulthood	 and	 adolescence.	 Consequently,	Chapter	 5	 will	
















Finally,	Chapter	 7	 will	 shift	 focus	 to	 the	 application	 of	 rsfMRI	 techniques	 in	 AD.	 The	most	
extensively	 studied	 and	 validated	 method	 for	 quantifying	 functional	 alterations	 in	 AD	 are	




retrosplenial	 cortices,	 also	 considered	 a	 central	 hub	 of	 the	 DMN,	 is	 not	 functionally	
homogeneous.	 In	 particular,	 the	 PMC	 has	 been	 shown	 to	 share	 a	 complex	 functional	
architecture	with	the	rest	of	the	brain	associating	with	several	intrinsically	stable	networks	as	
well	 as	 the	DMN.	Recent	work	has	begun	 to	demonstrate	 that	AD	pathogenesis	 leads	 to	a	
complex	 pattern	 of	 functional	 connectivity	 cascades	 of	 hyperconnectivity	 and	
hypoconnectivity,	and	cannot	alone	by	explained	by	the	DMN	disruptions.	Furthermore,	the	
prospect	 of	 rsfMRI	 techniques	 detecting	 functional	 alterations	 prior	 to	 structural	 atrophy	
provides	 a	 promising	 step	 to	 monitoring	 the	 disease	 earlier	 than	 current	 structural	 MRI	
methods.			
	
Using	 clinical	 phenotyping,	 metadata,	 and	 rsfMRI	 neuroimaging	 data,	 I	 will	 attempt	 to	
characterise	the	complex	functional	architecture	of	the	PMC	in	AD.	I	hypothesise	that	brain	
activity	 of	 the	 PMC	 region	 should	 reveal	 a	 complex	 and	 dynamic	 pattern	 of	 intrinsic	
connectivity	with	the	rest	of	the	brain.	Moreover,	key	regions	of	the	PMC	with	discrete	roles	
in	 supporting	 cognition,	 memory	 and	 attentional	 control	 will	 be	 affected	 in	 AD	 and	 MCI	
	 84	
patients	converting	to	the	disease.	A	disruption	in	the	functional	equilibrium	of	the	PMC	at	rest	





In	summary,	 this	 thesis	will	 investigate	the	utility	of	advanced	neuroimaging	techniques	 for	
detecting	AD,	across	several	complex	biomarker	phenotypes,	including	the	MCI	stage,	APOE	e4	
risk,	 abnormal	 Aβ	 accumulation,	 and	 cognitive	 decline.	 This	 thesis	 will	 address	 these	
investigations	by	establishing	several	key	aims:	 (1)	To	compare	an	automated	hippocampal	
subfield	 analysis	 technique	 over	 standard	 hippocampal	 volume	measurements	 for	 disease	
classification	and	prediction	(Chapter	2),	(2)	To	evaluate	the	prognostic	ability	of	alternative	
CSF	proteins	in	combination	with	structural	MRI	measurements	for	disease	classification	and	






































































































































































































































































































































































of	 late-onset	Alzheimer’s	disease	 (AD)	and	since	 its	discovery,	a	 large	body	of	 research	has	
been	conducted	to	explain	its	role	in	AD	pathophysiology	[1–3].	The	APOE	ε4	allele,	a	genetic	




Hippocampal	 volumetry	 has	 been	 shown	 to	 be	 a	 sensitive,	 albeit	 non-specific	 marker	 of	
neurodegeneration	 in	AD.	Previously,	 it	has	been	used	to	demonstrate	accelerated	rates	of	
hippocampal	 atrophy	 in	 ε4	 carriers	 with	 amnestic	 Mild	 Cognitive	 Impairment	 (MCI)	 [7,8].		
Although	 the	 exact	 temporospatial	 relationship	 between	 Aβ	 and	 tau	 in	 the	 pathological	
cascade	 of	 AD	 is	 unclear,	 it	 has	 been	 suggested	 that	 both	 proteinopathies	 may	 have	 a	
synergistic	effect	on	neuronal	toxicity	[9].	Emerging	data	also	suggests	that	these	pathological	
processes	that	influence	cognitive	decline	in	AD	are	moderated	by	APOE	ε4	through	both	Aβ-
dependent	 and	 Aβ-independent	 mechanisms	 [10].	 However,	 evidence	 for	 the	 direct	
mechanistic	actions	of	APOE	ε4	is	mixed.		
	















In	 order	 to	 capture	 the	 heterogeneity	 of	 varying	 AD	 risk,	 we	 combined	 several	 well-
characterised	 cohort	 studies	 to	 evaluate	 neuroanatomic	 the	 effect	 of	 APOE	 genotype	 on	


















linear	 effect	 of	 APOE	 genotype	 on	 disease	 risk,	 with	 ε2	 carriers	 possessing	 a	 low	 risk	 of	
developing	AD,	and	ε4	carriers	possessing	the	greatest	risk	[17].	We	aimed	to	test	if	this	linear	
stepwise	 effect	 of	 APOE	 genotype	 also	 imparted	 a	 similar	 neuroanatomic	 effect	 on	 the	
hippocampus	 across	 the	 different	 stages	 of	 AD	 pathophysiology.	 We	 then	 tested	 the	




may	 have	 downstream	 effects	 on	 tau	 neurodegeneration	 [18].	 To	 further	 elucidate	 the	
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Cohort	 specific	 inclusion	 criteria	 and	 details	 of	 the	 study	 design	 can	 be	 found	 in	 previous	






A	 detailed	 description	 of	 the	 study	 design	 can	 be	 found	 on	 the	 ADNI	 webpage	
(http://www.adni-info.org).	 Data	 was	 obtained	 for	 subjects	 from	 the	 ADNI	 online	
database	(adni.loni.usc.edu).	Subjects	were	between	55	and	90	years	of	age.	ADNI	was	





ii. MCI	 (n=383):	 (General	 inclusion/exclusion	 criteria):	 1)	 subjects	 had	 MMSE	
scores	 between	 24	 and	 30	 (inclusive).	 2)	 Memory	 complaint	 had	 objective	
memory	 loss	measured	 by	 education	 adjusted	 scores	 on	Wechsler	Memory	









Information	 regarding	 the	 study	 design	 and	 enrolment	 criteria	 has	 been	 previously	
described	 elsewhere	 [21,24].	 All	 AD	 and	 MCI	 subjects	 were	 recruited	 from	 the	 local	
memory	 clinics	 of	 one	 of	 the	 six	 participating	 sites	 while	 the	 control	 subjects	 were	
recruited	 from	non-related	members	of	 the	patient's	 families,	caregiver's	 relatives	and	
social	centres	for	the	elderly	or	GP	surgeries.	ANM	was	approved	by	the	South	London	
and	Maudsley	NHS	Foundation	Trust	ethics	committee	and	other	ethical	review	boards	of	
each	 participating	 country.	 Ethics	 committee	 approval	 was	 obtained	 at	 each	 of	 the	
participating	 centres	 in	 accordance	 with	 the	 Alzheimer’s	 Associations	 published	
recommendations.		
i. AD	 (n=109):	 (Inclusion	 criteria):	 1)	 ADRDA/NINCDS	 and	 DSM-IV	 criteria	 for	
probable	Alzheimer's	disease.	2)	Mini	Mental	State	Examination	score	ranged	

















The	 AIBL	 study	 is	 a	 prospective	 longitudinal	 study	 of	 aging,	 integrating	 data	 from	
neuroimaging,	 biomarkers,	 lifestyle,	 clinical	 and	 neuropsychological	 analysis.	 Detailed	
information	about	the	study	design	has	been	described	in	previous	publications	[20,25].	
CN	 individuals	 were	 recruited	 by	 advertisement	 in	 the	 community	 while	 MCI	 and	 AD	
patients	 were	 recruited	 from	 tertiary	memory	 disorders	 clinics	 or	 private	 geriatricians,	
psychiatrists	and	neurologists	that	subspecialise	in	dementia.	All	participants	were	at	least	
60	 years	of	 age,	 in	 good	general	health	with	no	history	of	 stroke	or	other	neurological	















4) Biomedical	 Research	 Centre	 for	 Mental	 Health	 and	 Dementia	 Cohort,	 King’s	 College	
London	(BRC-AD)	(n=89)	
BRC-AD	is	a	neuroimaging	study	which	was	designed	to	establish	imaging	markers	for	the	
earlier	detection	and	diagnosis	of	AD.	Data	was	 collected	at	 the	 Institute	of	Psychiatry,	
Psychology,	and	Neuroscience	(IoPPN),	King’s	College	London,	UK.	A	total	of	89	subjects	





Participants	 were	 recruited	 from	 a	 larger	 population-based	 epidemiological	 study,	 the	
Swedish	 National	 study	 on	 Ageing	 and	 Care	 in	 Kungsholmen	 (SNAC-K).	 In	 this	 study,	
participants	were	randomly	selected	to	take	part	from	the	island	of	Kungsholmen	in	central	




disease,	 or	 epilepsy,	 were	 excluded.	 The	 study	 design	 has	 been	 described	 in	 detail	
elsewhere	[22].	We	used	a	sample	of	459	individuals	from	SNAC-K,	who	underwent	MRI	
imaging	and	APOE	genotyping.	77	subjects	with	suboptimal	MRI	images	and	neurological	
and/or	 psychiatric	 conditions	 were	 excluded.	 The	 SNAC-K	 study	was	 population-based,	









This	 is	 the	 first	 European	 multi-centre	 study	 combining	 genetics	 with	 behavioural	 and	
neuropsychological	 measures,	 functional	 and	 structural	 neuroimaging	 and	 genome-wide	
association	analyses	in	2000	healthy	14-year-old	adolescents.	A	description	of	the	study	design	




CA,	 USA).	 Quality	 control	 of	 the	 genome-wide	 data	 was	 performed	 and	 samples	 with	 the	
following	 criteria	 were	 excluded:	 genotype	 call	 rate	 <95%,	 and	 those	 with	 discordance	
between	clinical	and	genotypic	gender.		Single	Nucleotide	Polymorphisms	(SNP)	quality	control	
ﬁlters	 were	 used	 as	 described	 in	 the	 ENIGMA	 consortium	 imputation	 protocol	
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AIBL:	 T1-weighted	 MRI	 was	 obtained	 using	 the	 ADNI	 3D	 Magnetization	 Prepared	 Rapid	
Gradient	 Echo	 (MPRAGE)	 sequence,	 with	 1x1mm	 in-plane	 resolution	 and	 1.2mm	 slice	
thickness,	TR/TE/T1=2300/2.98/900,	flip	angle	9°	and	field	of	view	240x256	and	160	slices.	T2	
FSE	 and	 FLAIR	 sequences	 were	 also	 obtained.	 The	 AIBL	 protocol	 has	 been	 described	 in	
extensive	detail	previously	[20].		
	




























(Aβ+)	 and	 Aβ	 negative	 (Aβ-).	 PiB	 participants	were	 classified	 as	 Aβ+	when	 the	measure	 of	







Volumetric	 segmentation	 of	 the	 hippocampus	 was	 performed	 using	 FreeSurfer	 (5.1.0).	
FreeSurfer	utilises	an	affine	rigid	linear	transformation	and	combines	spatial	information	about	










images	 were	 performed	 by	 visualising	 the	 subcortical	 segmentation	 borders	 of	 the	










were	excluded	 from	the	analysis	due	to	 the	opposing	protective	effect	of	 the	ε2	allele	and	

























significant	 linear	 stepwise	 reduction	 in	hippocampal	 volume	was	observed	with	 ε2	 carriers	
possessing	the	largest	volumes,	ε3	carriers	possessing	intermediate	volumes	and	ε4	carriers	
possessing	the	smallest	volumes.	This	pattern	was	also	observed	in	the	MCI	group	(Table	3).	
























ε4+	 CN	 individuals,	 hippocampal	 volumes	 between	 Aβ+	 and	 Aβ-	 participants	 did	 not	
significantly	differ	(left	region:	p	=	0.692;	right	region:	p	=	0.946).	MCI	Aβ+	participants	were	













Prior	 neuroimaging	 studies	 of	 APOE	 ε4	 have	 helped	 define	 our	 current	 observation	 of	
structural	changes	in	the	brain,	but	the	mechanisms	associated	with	the	detrimental	effect	of	
APOE	ε4,	particularly	across	the	different	stages	of	AD,	still	remains	poorly	understood.		With	
recent	 studies	proposing	 a	neurodevelopmental	 foothold	of	APOE	ε4	on	 the	brain	 [43,44],	




Here	 we	 present	 the	 largest	 cross-sectional	 multi-cohort	 study	 of	 APOE	 and	 hippocampal	
volume	to	date	(n=3168)	and	discuss	a	number	of	key	findings.			Firstly,	a	linear	neuroanatomic	
effect	of	the	APOE	genotype	was	observed	for	hippocampal	volumes	of	AD	and	MCI	subjects,	












The	 absence	 of	 APOE-dependent	 hippocampal	 volume	 loss	 in	 CN	 individuals	 and	 in	 a	











To	 test	 whether	 an	 Aβ-dependent	 effect	 of	 APOE	 ε4	 would	 be	 associated	 with	 greater	



















that	 there	 were	 no	 hippocampal	 volume	 differences	 present	 between	 the	 APOE	 groups,	
suggesting	that	ε4	carriers	are	unlikely	to	be	at	risk	in	adolescence,	but	may	perhaps	develop	
a	greater	risk	later	in	life.	Similar	studies,	such	as	that	of	O’Dwyer	and	colleagues	[15]	reported	


















and	 were	 of	 Caucasian	 background.	 As	 such,	 future	 prospective	 studies	 with	 more	
representative	samples	should	be	conducted	to	address	how	these	comorbidities,	namely	the	
presence	 of	 vascular	 disease,	 could	 potentially	 influence	 the	 size	 of	 the	 hippocampus.	We	
demonstrated	 that	 systematic	 bias	 was	 not	 present	 in	 our	 dataset	 when	 comparing	
hippocampal	 volumes	 between	 APOE	 groups	 within	 each	 cohort	 study	 separately	
(Supplementary	 Information).Additional	 factors	 such	 as	 the	 use	 of	 two	 different	 PET	
radioligands	meant	 that	 SUVR	 values	 of	 tracer	 uptake	 could	 not	 be	 compared	 as	 a	 single	
continuous	 measure.	 However,	 ongoing	 working	 groups	 such	 as	 the	 Centiloid	 project	 will	







gene	 polymorphisms	 on	 hippocampal	 volume.	 An	 independent	 sample	 of	 healthy	 14yr	 old	






show	 APOE	 ε4	 dependent	 changes	 in	 the	 hippocampus,	 suggesting	 that	 the	 relationship	
between	APOE	ε4	and	Aβ	may	be	mediated	by	the	presence	of	neurodegeneration.	The	same	
pattern	 was	 also	 observed	 in	 healthy	 young	 adolescents	 who	 possessed	 no	 hippocampal	
differences	between	different	APOE	groups.	Our	study	thus	shows	hippocampal	volume	loss	is	
moderated	by	APOE	ε4	and	Aβ	in	AD	and	the	MCI	stages	of	the	AD	pathological	process.	The	














which	 was	 made	 available	 at	 the	 ADNI	 database	 (www.loni.ucla.edu/ADNI).	 The	 AIBL	
researchers	contributed	data	but	did	not	participate	in	analysis	or	writing	of	this	report.	AIBL	
researchers	can	be	found	on	the	AIBL	website	(aibl.csiro.au).	(3)	Data	used	in	the	preparation	
of	 this	 study	 was	 obtained	 from	 the	 AddNeuroMed	 study	 which	 was	 was	 supported	 by	
InnoMed,	 (Innovative	Medicines	 in	 Europe)	 an	 Integrated	 Project	 funded	 by	 the	 European	




Study	 of	 Ageing	 and	 Care	 in	 Kungsholmen	 (SNACK)	 which	was	 supported	 by	 Stiftelsen	 för	




IMAGEN	 project,	 which	 receives	 research	 funding	 from	 the	 European	 Community’s	 Sixth	
Framework	Program	(LSHM-CT-2007-037286)	and	coordinated	project	ADAMS	(242257),	as	
well	as	the	NIHR	Biomedical	Research	Centre	for	Mental	Health	and	NIHR	Biomedical	Research	
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CHAPTER	 6:	 TRACT	 BASED	 SPATIAL	 STATISTIC	 REVEALS	 NO	
DIFFERENCES	 IN	 WHITE	 MATTER	 MICROSTRUCTURAL	









































































CHAPTER	 7:	 DISTINCT	 FUNCTIONAL	 PROPERTIES	 OF	 THE	
POSTEROMEDIAL	 CORTEX	 REVEAL	 ABERRANT	 FUNCTIONAL	























clinical	 phenotyping	 and	metadata,	 I	 report	 a	 resting-state	 functional	magnetic	 resonance	
imaging	 study	 in	 the	 Alzheimer’s	 Disease	 Neuroimaging	 Initiative	 (ADNI)	 dataset,	 to	
characterise	a	pattern	of	PMC	functional	heterogeneity	with	the	rest	of	the	brain.	The	PMC	
subdivisions	were	found	to	be	consistent	with	previous	anatomical	studies	in	the	monkey	brain	
and	 functional	 imaging	 studies	 of	 the	human	PMC.	 The	main	 findings	were	 (i)	 AD	patients	
demonstrated	 hyperconnectivity	 of	 the	 dorsal	 posterior	 cingulate	 region	 with	 the	 DMN	
compared	 to	cognitively	normal	 (CN)	 individuals,	 (ii)	 there	was	a	connectivity	 failure	of	 the	
retrosplenial	cortex	supporting	memory	and	cognition,	and	a	frontal	hyperconnectivity	burden	
in	AD	patients,	and	(iii)	MCI	subjects	that	converted	to	AD	at	a	two	year	follow-up	displayed	










activity,	 believed	 to	 reflect	 the	 integrated	 synaptic	 activity	 of	 neuronal	 firing	 via	MR	 signal	
changes	 due	 to	 changes	 in	 blood	 flow,	 blood	 volume,	 and	 the	 blood	
oxyhaemoglobin/deoxyhaemoglobin	 ratio	 [1–3].	 Recently,	 considerable	 interest	 has	 been	
focused	on	 the	 intrinsic	 functional	 connectivity	 of	 large-scale	brain	networks	 at	 rest,	 often	
referred	to	as	resting-state	fMRI	(rsfMRI).	These	techniques	evaluate	the	correlation	between	
intrinsic	 oscillations	 or	 timecourse	 of	 the	 BOLD	 signal	 between	 brain	 regions,	 and	 have	




level	 memory	 and	 cognitive	 processes	 are	 subserved	 by	 a	 heteromodal	 network	 of	 brain	
regions	collectively	known	as	the	Default-Mode	Network	(DMN)	[6,7].	Anatomically,	the	DMN	
consists	of	prominent	nodes	in	the	posterior	cingulate	cortex	(PCC),	ventromedial	prefrontal	
















with	 memory,	 but	 has	 also	 been	 linked	 to	 several	 other	 non-memory	 systems	 (language,	
visuospatial,	attentional,	and	executive	systems)	[17].		
	
A	 seminal	 study	 by	 Andrews-Hanna	 and	 colleagues	 [18]	 showed	 that	 the	 DMN	 could	 be	
topographically	divided	into	subsystems	each	serving	discrete	functional	roles.	The	DMN	was	
segregated	into	three	core	subsystems:		comprised	of:	(1)	a	midline	core	system,	containing	
the	PCC,	and	anterior	medial	prefrontal	 cortex	 (aMPFC),	 (2)	a	MTL	system	and	 (3)	a	dorsal	
medial	 prefrontal	 cortex	 (dMPFC)	 system.	 Previous	 work	 has	 shown	 that	 the	 pattern	 of	
connectivity	changes	differs	between	these	subsystem	regions,	with	decreased	connectivity	in	
the	PCC	and	MTL,	and	increases	 in	the	medial	frontal	regions	 in	AD	[15].	Further	functional	
brain	 parcellation	 methods	 identified	 several	 subsystems	 within	 one	 module	 that	
encompassed	all	the	subsystems	identified	by	Andrews-Hanna	et	al,	termed	the	task-negative	












with	 the	 rest	 of	 the	 cortex.	 This	 current	work	 addresses	 this	 open	 question	 regarding	 the	




















[26].	 Within	 the	 PMC,	 the	 PCC	 also	 displays	 considerable	 functional	 heterogeneity	 where	




















































This	 illustration	 provides	 a	 clear	 summary	 of	 the	
functional	 connectivity	 patterns	 	 emerging	 from	 the	
three	 subdivisions	 of	 the	 precuneus	 identified	 by	
Margulies	et	al	[26].	In	blue,	the	anterior	zone	along	the	
marginal	 ramus	 of	 the	 cingulate	 sulcus	 displays	
connectivity	with	 sensorimotor	 regions.	 In	green,	 the	
central	precuneal	region	displays	connectivity	with	the	
posterior	 part	 of	 the	 inferior	 parietal	 lobule	 and	
adjacent	 superior	 temporal	 sulcus.	 In	 yellow,	 the	
posterior	 zone,	 along	 the	 parieto-occipital	 fissure	




















function	 in	a	 range	of	psychiatric	and	neurological	 conditions,	 some	of	which	are	potential	









(v23a	 and	 v23b,	 posterior	 31).	 The	 dorsal	 PCC	 reveals	 a	 selective	 pattern	 of	 functional	
connectivity	 with	 connections	 to	 the	 DMN	 and	 other	 intrinsic	 networks	 such	 as	 the	
frontoparietal	 networks	 that	 encompass	 the	 attentional	 network,	 as	 well	 as	 with	 other	
networks	 involved	 in	 executive	 control	 [33,26].	 	 By	 contrast,	 the	 ventral	 PCC	 shows	 strong	
connectivity	with	the	DMN	during	internally	focused	states	(such	as	resting-sate)	[28,34].	This	






networks,	 several	 critical	 questions	 regarding	 the	 integrity	 of	 the	 PMC	 in	 AD	 remain	
unaddressed.	For	one,	only	a	small	number	of	studies	have	addressed	the	question	of	PMC	
function	 in	 AD	 pathophysiology	 [35,36].	 Additionally,	 little	 is	 known	 about	 the	 functional	
heterogeneity	 of	 the	 PMC	 and	 how	 it	 interacts	with	 the	 rest	 of	 the	 brain,	 as	well	 as	with	



















(ADNI)	 database	 (http://adni.loni.usc.edu/).	 The	 ADNI	 study	 was	 launched	 in	 2003	 by	 the	
National	Institute	on	Aging,	the	National	Institute	of	Biomedical	Imaging	and	Bioengineering,	
the	 Food	 and	 Drug	 Administration,	 private	 pharmaceutical	 companies,	 and	 non-profit	
organizations	as	a	$60	million,	5-	year	public–private	partnership.	The	primary	goal	of	ADNI	has	
been	 to	 test	 whether	 serial	 MRI,	 PET,	 other	 biological	 markers,	 and	 clinical	 and	
neuropsychological	assessment	can	be	combined	to	measure	the	progression	of	mild	cognitive	
impairment	and	early	Alzheimer’s	disease.	Determination	of	sensitive	and	specific	markers	of	












unavailable	 during	 baseline	 visit	 (n=22),	 these	 subjects	 were	 not	 included	 for	 further	
preprocessing	and	analysis.	 Subjects	were	 classified	as	Aβ-positive	 (Aβ+)	using	a	previously	
defined	 cut-off	 (1.11	 SUVR)	using	 the	whole	 cerebellum	 region	 for	 Florbetapir	Aβ	 imaging.	
















All	 subjects	 were	 scanned	 using	 a	 3T	 Philips	 system.	 Task-free	 functional	MRI	 scans	 were	
obtained	 using	 a	 single	 shot	 gradient	 echo-planar	 imaging	 sequence	 (EPI)	 with	 full	 brain	
coverage	including	the	whole	cerebellum.	The	following	parameters	were	used:		140	functional	
volumes,	repetition/echo	time	of	3000/30ms,	flip	angle	of	80°,	48	axial	slices,	and	a	64	x	64	in-
plane	acquisition	matrix	 reconstructed	 to	produce	slice	 thickness	of	3.3mm	and	a	 isotropic	











study-specific	 custom	 template	 using	 the	 Diffeomorphic	 Anatomical	 Registration	 Through	











The	 initial	 preprocessing	 steps	 involved	 discarding	 the	 first	 10	 functional	 volumes	 of	 the	






















the	PCC	and	Precuneus	 regions	using	 the	Harvard-Oxford	probabilistic	 atlas	 in	 fslview	 [45].	
These	regions	were	defined	by	only	selecting	voxels	with	a	probability	greater	than	20%	signal	
intensity	and	concatenating	both	anatomical	masks	to	form	the	PMC.	For	the	PCC	region,	the	



















GLM	 was	 used,	 this	 time	 entering	 whole-brain	 fMRI	 data.	 The	 time	 courses	 of	 the	 PMC	
subregions	calculated	in	the	previous	step	were	simultaneously	included	in	the	design	matrix	






design	matrix	 simultaneously	with	 the	 spatial	maps	 from	 the	 10	 component	 ICA	 step.	We	
defined	the	MTL	node	using	the	Harvard-Oxford	subcortical	probabilistic	atlas	in	fslview	(voxels	
>	 20%	 probability)	 by	 creating	 an	 anatomical	 mask	 of	 the	 hippocampal,	 entorhinal,	 and	
parahippocampal	 structures.	On	 the	other	hand,	 the	VMPFC	was	created	 from	Neurosynth	
(http://www.neurosynth.org/)	using	the	reverse	inference	map	and	thresholded	using	p	=	<	
0.0001	uncorrected,	after	smoothing	the	Z-map	with	a	6mm	FWHM	kernel	and	averaging	the	
z-scores	 from	 the	 right	 and	 left	 hemispheres	 to	 create	 a	 symmetrical	 mask.	 We	 then	
investigated	whether	these	10	independent	signals	from	each	PMC	subregion	correlated	with	
the	activity	 in	the	MTL	and	VMPFC	nodes.	Therefore,	 in	the	second	GLM	fMRI	activity	from	
within	 the	MTL	and	VMPFC	nodes	was	entered	along	with	 the	 time	courses	 from	the	PMC	
subregions	in	the	design	matrix.	This	subsequently	generated	a	set	of	voxelwise	statistical	maps	





Finally,	 the	 resulting	voxelwise	 spatial	maps	 from	each	analysis	 step	above	were	combined	
separately	 for	 the	 PMC	whole-brain	 analysis	 and	 the	 PMC-MTL	 and	 PMC-VMPFC	 analyses	





















Consistent	 with	 the	 proposed	 functional	 heterogeneity	 of	 the	 PMC,	 we	 found	 that	 the	 3	














of	 the	 brain.	 Strong	 connections	 were	 observed	 with	 the	 paracentral	 lobule	 and	


















consistent	 with	 what	 has	 been	 reported	 in	 the	 literature,	 with	 distinct	 cytoarchitectonics	
within	the	PCC,	suggesting	separation	into	dorsal	and	ventral	areas	[32].	Here,	we	identified	3	
subregions	that	revealed	the	functional	subdivisions	of	the	PCC	at	rest.	The	dorsal	PCC	was	
found	 to	 be	 anchored	 across	 two	 intrinsic	 networks,	 consistent	 with	 previous	 evidence	
suggesting	 involvement	 in	 several	 networks	 for	maintaining	whole-brain	metastability	 [50].	
Moreover,	the	dorsal	PCC	was	found	to	be	divided	into	two	regions:	the	predominately	dorsal	
zone	and	anterior	dorsal	 region.	By	contrast,	 the	ventral	PCC	was	only	associated	with	 the	
DMN.	 Two	 dorsal	 PCC	 subregions	 were	 identified	 with	 connections	 in	 both	 the	 DMN	 and	
central	executive	network.	This	 suggests	 that	 the	dorsal	PCC	may	act	as	 interface	between	
these	 two	 networks	 primarily	 involved	 in	 cognitive	 and	 attentional	 control	 [28].	 The	
subdivisions	 of	 the	 PCC	 and	 their	 functional	 connectivity	 with	 whole-brain	 networks	 are	
displayed	in	Figure	5.		
	
(1) Dorsal	 PCC	 (DMN):	 The	 second	 PCC	 signal	 in	 the	 dorsal	 region	 showed	 functional	
connectivity	with	the	DMN,	particularly	the	entire	PCC	region,	the	VMPFC	node,	and	
the	parahippocampal	gyrus.		




















the	 cuneus	 along	 the	 parieto-occipital	 fissure.	 More	 specifically,	 this	 subregion	
demonstrated	strong	functional	connectivity	with	the	visual	cortex	(BA17	and	BA18).		
	
Overall,	 separate	 rsfMRI	signals	 from	the	PMC	were	 found	 to	be	correlated	with	activity	 in	
several	other	brain	networks.	Spatially	overlapping	whole-brain	functional	connectivity	maps	
of	our	independent	PMC	signals	also	demonstrated	the	greatest	spatial	overlap	in	the	dorsal	
PCC	 region	 (Figure	 7).	 This	 is	 consistent	with	 previous	work	 suggesting	 a	 strong	 functional	
connectivity	 pattern	 of	 the	 dorsal	 PCC	with	 a	wide	 range	of	 other	 intrinsic	 brain	 networks	
[26,27].	 Although	 the	 exact	 composition	 and	 spatial	 topology	 of	 the	 regions	 of	 interest	
extracted	 from	 the	 PMC	 region	 is	 sensitive	 to	 the	 number	 of	 independent	 components	







region	 (Figure	 9A).	 This	 dorsal	 PCC	 subregion	 showed	 functional	 connectivity	with	 regions	
typically	 involved	 in	 the	DMN	at	 the	whole-brain	 level.	Dorsal	PCC	hyperconnectivity	 in	AD	







functional	 connectivity	with	MTL	 in	AD	patients	 (Figure	9B).	 For	 the	RSC	 subregion	 (BA29),	
hypoconnectivity	in	the	MTL	region	was	observed	in	the	left	entorhinal	cortex	(p	=	0.01;	FWE	
corrected).	 For	 the	posterior	precuneal	 region,	hypoconnectivity	was	observed	 in	 the	 right	
entorhinal	 cortex	 and	 right	 subiculum	 (p	 =	 0.01;	 FWE	 corrected).	 There	 were	 no	 PMC	
































Relative	 to	 the	 CN	 group,	 MCI-converters	 also	 showed	 a	 similar	 pattern	 of	 frontal	
hyperconnectivity	with	the	VMPFC	for	the	RSC	(BA29)	subregion	(Figure	10C).	This	pattern	of	
hyperconnectivity	 in	 MCI-converters	 was	 detected	 in	 the	 left	 subcallosal	 cortex	 and	
paracingulate	 gyrus	 (p	 =	 0.03;	 FWE	 corrected).	 MCI-converters	 also	 exhibited	 reduced	
functional	connectivity	with	VMPFC	for	the	dorsal	PCC	subregion	compared	to	the	CN	group	








extend	 recent	 neuroimaging	 evidence	 from	 studies	 of	 the	 DMN	 to	 show	 the	 functionally	
heterogeneous	profile	of	the	PMC	and	its	vulnerability	to	AD	pathogenesis.		
	




connectivity	 cascades	 to	 AD	patients.	 In	 previous	 studies,	 clear	 dissociations	 are	 not	 often	
made	between	the	complex	functional	assembly	of	the	PCC	and	the	precuneus.	In	this	study,	









the	 visual	 prestriate	 areas	 in	 the	 cuneus	 and	 the	 dorsal	 lateral	 occipital	 region.	 This	




we	 ascribed	 as	 reflecting	 the	 DMN	 has	 also	 been	 associated	 with	 earlier	 reports	 of	 a	
frontoparietal	 control	 system	 [53,54].	 The	 inclusion	of	 the	precuneus	 in	 the	DMN	 is	 a	 less	






should	 be	 considered	 preliminary.	 Despite	 this,	 we	 would	 argue	 that	 consistency	 in	 the	








appeared	 to	 show	 more	 extensive	 connectivity.	 This	 is	 reflected	 in	 its	 densest	 structural	
connections	to	areas	of	the	heteromodal	association	cortex.	On	the	other	hand,	the	ventral	











functional	 connectivity	 with	 the	 DMN,	 particularly	 since	 the	 densities	 of	 hippocampal	




several	 fMRI	studies	highlighting	 its	 role	 in	spatial	navigation	and	episodic	memory	 [63,64].	
These	distinct	patterns	of	functional	connectivity	in	the	RSC	have	also	been	linked	to	processes	
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associated	with	mentally	 generating	 a	 complex	 and	 coherent	 scene	 –	which	 is	 believed	 to	












such	 differences	 were	 noted	 included	 the	 ventral	 PCC	 region	 of	 the	 DMN.	 	 This	 region	
demonstrates	 the	 densest	 reciprocal	 connections	 within	 the	 PCC	 [25]	 and	 exhibits	 strong	
structural	 connections	with	 the	MTL	 via	 the	 cingulum	bundle	 [7].	 This	 is	 contrary	 to	 some	
previous	 findings	 that	have	observed	 significant	decreases	 in	 functional	 connectivity	 in	 the	
PMC	 when	 characterising	 DMN	 failure	 in	 AD	 patients.	 Although	 commonly	 observed	








the	 case	 of	 the	 PCC.	We	 speculate	 that	 the	 dorsal	 PCC	 hyperconnectivity	 detected	 in	 the	
ventral	PCC	 region	may	be	 related	 to	 its	dense	connections	with	 the	MTL.	 In	AD,	 it	 can	be	
understood	that	MTL	networks	 (including	the	hippocampus	that	support	memory)	begin	to	
succumb	to	degeneration,	 increased	noise	and	processing	burden	 in	 these	cortical	 systems	
which	then	gets	propagated	back	to	hub	regions	such	as	the	PCC.	This	is	further	supported	by	
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properties	 of	 the	 PMC	 and	 to	 describe	 its	 functional	 heterogeneity	 with	 different	 brain	
networks.	 	 We	 therefore	 argue	 that	 a	 systems	 conceptualisation	 of	 solely	 decreases	 in	






network.	 Interestingly,	 the	 RSC	 BA29	 subregion	 also	 exhibited	 functional	 connectivity	with	
regions	collectively	forming	the	DMN.	The	decrease	in	functional	connectivity	observed	in	the	
MTL	network	was	detected	in	the	entorhinal	cortex	in	AD	patients	compared	to	CN	individuals.	




eventually	 leading	 to	 cognitive	 impairment.	 Furthermore,	 histological	 studies	 by	Braak	 and	
Braak	[70]	show	that	tau	pathology	in	later	stages	of	AD	is	diffuse,	affecting	the	MTL	regions	
first	followed	by	posterolateral	cortical	regions	and	the	frontal	cortex.	In	line	with	this	research,	







To	 evaluate	 previous	 reports	 of	 frontal	 hyperconnectivity	 in	 AD	 patients,	 we	 tested	 the	
functional	connectivity	of	PMC	subregions	with	the	VMPFC	node	of	the	DMN.	Consistent	with	
previous	 findings,	we	 found	 that	 the	 ventral	 PCC	 subregion	 displayed	 increased	 functional	
connectivity	with	the	VMPFC	node	in	AD	patients	compared	CN	individuals	[14,16,20].	These	
differences	were	detected	in	the	frontal	pole	and	frontal	medial	cortex	regions	of	the	VMPFC.	
Previously,	 frontal	 hyperconnectivity	 patterns	 in	 the	 later	 stages	of	AD	have	been	 typically	






posterior	 networks	 in	 memory	 functioning,	 it	 is	 unclear	 that	 frontal	 hyperconnectivity	
successfully	facilitates	an	adaptive	compensatory	response	to	continued	memory	processing.	






the	PMC	 in	MCI	patients,	we	 retrospectively	 selected	 individuals	 that	progressed	 to	an	AD	
diagnosis	 at	 future	 follow-up.	 Although	 we	 did	 not	 detect	 significant	 differences	 in	 PMC-
derived	 networks	 at	 the	 whole-brain	 level,	 similar	 functional	 connectivity	 patterns	 to	 AD	
patients	 in	 the	 MTL	 and	 VMPFC	 nodes	 of	 the	 DMN	 were	 observed.	 Firstly,	 precuneal	
subregions	 of	 the	 PMC	 functionally	 coupled	 with	 the	MTL	 node	 of	 the	 DMN	were	 widely	
disrupted	in	MCI-converters.	In	particular,	the	central	precuneal	subregion	showed	decreased	






role	 in	 DMN	 activity	 and	 memory	 breakdown	 in	 AD	 pathogenesis	 [49].	 Interestingly,	 the	
anterior	 precuneal	 region	 also	 showed	 decreased	 functional	 connectivity	 with	 the	 MTL	
network.	 Target	 brain	 regions	 of	 the	 MTL	 affected	 included	 the	 entorhinal	 cortex	 and	
subiculum	 region	 of	 the	 hippocampus.	 Although	 the	 anterior	 precuneal	 region	 typically	
exhibits	functional	connectivity	with	sensorimotor	regions,	its	functional	coupling	with	the	MTL	
has	been	linked	to	cognitive	processes	such	as	the	internal	representation	of	self	and	episodic	












prominent	MTL	 regions.	 Consequently,	 they	 concluded	 that	 additional	 neural	 information-
processing	resources	in	prefrontal	regions	are	used	to	compensate	for	cognitive	dysfunction.	
Damoiseaux	 [76]	 further	 proposed	 that,	 within	 the	 DMN,	 hyperconnectivity	 manifests	
upstream	to	hypoconnectivity	 in	aberrant	functional	cascades	during	different	stages	of	AD	




declining	 MTL	 cortical	 systems	 could	 explain	 the	 hyperconnectivity	 in	 well-connected	
prefrontal	 regions.	 What	 is	 clear	 is	 that	 these	 functional	 characteristics	 of	 frontal	




discrete	 regions	 that	 participate	 in	 distinct	 functional	 networks.	 Our	 evidence	 suggests	 a	
selective	 vulnerability	 of	 the	 dorsal	 PCC	 in	 AD	 and	MCI	 patients	with	 prodromal	 stages	 of	










related	 circuits,	 particularly	 in	 the	 ROI	 definition	 of	 the	 VMPFC	 region.	 This	 was	 done	 by	
creating	an	averaged	mask	of	temporal	signal-to-noise	ratio	across	our	sample	to	ensure	that	
ROIs	 predominately	 avoided	 regions	 of	 high	 signal-to-noise.	 It	 would	 also	 be	 important	 to	
extend	this	work	to	patients	with	preclinical	stages	of	AD	that	display	little	or	no	overt	signs	of	
memory	 decline.	 Several	 key	 findings	 in	 PMC	 connectivity	 disruption	were	 associated	with	
cortical	 connections	 with	 MTL	 circuits	 responsible	 for	 supporting	 memory	 and	 cognition.	
Future	work	should	consider	testing	the	relation	of	PMC	vulnerability	in	AD	pathophysiology	
with	cognitive/clinical	measures	to	assess	whether	they	are	predictive	of	severity.	At	present,	
there	 are	 no	 comparable	 studies	 evaluating	 PMC	 heterogeneity	 using	 the	 methodological	
approach	outlined	in	this	study.	Consequently,	we	sought	to	understand	PMC	vulnerability	in	
AD	patients	and	MCI	subjects	that	are	known	to	convert	to	AD	at	future	follow-up.	To	fully	
characterise	 the	 functional	 connectivity	 cascades	 of	 the	 PMC,	 it	would	 also	 be	 valuable	 to	
assess	the	connectivity	patterns	of	preclinical	subjects	with	little	or	no	memory	decline.		
	




heterogeneity	 is	 important	 for	 understanding	 the	 complex	 connectivity	 patterns	 in	 AD	
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Figure	 19:	 Functional	 overlap	 of	 8	 out	 of	 10	 resulting	 whole-brain	 networks	 from	
posteromedial	cortex	signals	
Here,	we	illustrate	the	spatial	overlap	from	the	resulting	whole-brain	networks	of	8	out	of	10	
independent	 posteromedial	 cortex	 signals.	 Warmer	 colours	 indicate	 the	 highest	 overlap	


















































































with	 MTL	 in	 central	 precuneal	 region	 compared	 to	 CN	 individuals	 (CN	 >	 MCIc).	 (B)	 MCI-converters	 show	 reduced	
connectivity	 with	 MTL	 in	 anterior	 precuneal	 region	 compared	 to	 CN	 individuals	 (CN	 >	 MCIc).	 (C)	 MCI-converters	





The	 key	 aims	 of	 this	 thesis	 were:	 (1)	 To	 compare	 a	 new	 automated	 hippocampal	 subfield	
analysis	technique	over	standard	hippocampal	volume	measurements	for	disease	classification	
and	 prediction	 (Chapter	 2),	 (2)	 Testing	 the	 diagnostic	 and	 predictive	 ability	 of	 combining	
alternative	CSF	candidates	with	structural	MRI	markers	 for	AD	classification	and	MCI	 to	AD	
conversion	 prediction	 (Chapter	 3),	 (3)	 To	 assess	 the	 effect	 of	 different	 APOE	 gene	
polymorphisms	 on	 hippocampal	 volume	 and	 Aβ	 deposition	 in	 a	 large	 multi-cohort	 study	
(Chapter	4),	(4)	To	explore	the	neurodevelopmental	relationship	between	the	APOE	gene	and	
brain	structure	in	a	large	sample	of	healthy	14-yr	old	adolescents	(Chapters	5	and	6),		and	(5)	





In	 Chapter	 2,	 I	 investigated	 the	 effectiveness	 of	 a	 relatively	 new	 automated	 hippocampal	


















and	 the	 presence	 of	 hippocampal	 cysts	 which	 can	 further	 exacerbate	 this	 problem.	 New	
initiatives,	 such	as	 the	EADC-ADNI	Harmonized	Hippocampal	Protocol	 (HarP)	 [1]	have	been	
established	 for	 defining	 a	 harmonized	 protocol	 for	 the	 manual	 segmentation	 of	 the	
hippocampus.	 Similar	 initiatives	 and	 quality-control	 studies	 comparing	 the	 effectiveness	 of	
automated	and	manual	hippocampal	subfield	measurements	would	further	help	in	addressing	
this	methodological	issue.	Recent	quantitative	comparisons	of	manual	segmentation	protocols	
for	 labelling	 hippocampal	 substructures	 provide	 possible	 strategies	 towards	 developing	 a	
harmonized	protocol	[2].	Furthermore,	a	new	longitudinal	method	for	automated	hippocampal	
segmentation	 will	 provide	 more	 localised	 and	 accurate	 method	 for	 quantification	 [3],	
particularly	 for	 atrophy	 rates	 that	 are	 useful	 for	 tracking	 AD	 progression.	 Another	 issue	
highlighted	in	the	chapter	was	the	specificity	of	our	predictive	models	for	MCI	classification.	
Although	 the	 sensitivity	 of	 classifiers	 in	 predicting	MCI	 patients	 that	 converted	 to	 AD	was	
generally	good,	specificity	was	limited	in	predicting	those	that	did	not	convert	to	AD	at	the	time	
of	 follow-up.	 Since	 AD	 symptomatology	 sufficient	 for	 diagnosis	 may	 take	 several	 years	 to	
manifest,	limited	specificity	could	be	attributed	to	a	short-follow	up.	Future	studies	with	longer	
follow-up	 times	 would	 determine	 whether	 many	 of	 the	 MCI	 subjects	 misclassified	 as	
converting	to	AD	will	indeed	convert	at	some	point	in	the	future.		
	
To	 address	 limitations	 in	 specificity,	 recent	 evidence	 has	 suggested	 that	 the	 effective	










To	 address	 this	 issue,	 in	 Chapter	 3,	 I	 tested	 alternative	 CSF	 proteins	 associated	 with	




of	 proteins,	 I	 aimed	 to	 determine	 whether	 a	 novel	 subset	 of	 proteins	 could	 improve	 the	
diagnostic	accuracy	and	predictive	ability	of	MRI	and	CSF	biomarkers.		
	




MRI	and	CSF	biomarker	model.	Given	 the	multifactorial	nature	of	AD	pathophysiology,	 it	 is	
likely	 that	 these	 CSF	 proteins,	 though	 not	 complimentary	 for	 AD	 detection,	might	 possess	
significant	 prognostic	 potential	 for	 predicting	MCI	 individuals	 likely	 to	 convert	 to	 AD.	 As	 a	
result,	I	then	tested	whether	this	same	subset	panel	could	complement	regional	MRI	measures	
and	CSF	biomarkers	 for	predicting	MCI	 to	AD	conversion	at	a	one	year	 follow-up.	The	MCI	





CSF	candidates	can	complement	other	biomarkers	 for	 improved	disease	prediction	 [10,11].	
This	was	the	first	neuroimaging	study	to	show	that	candidate	CSF	proteins	of	inflammation,	






























hippocampal	 differences	 than	 Aβ-	 e4+	 participants	 in	 general,	 there	were	 no	 hippocampal	
differences	in	these	two	groups	within	the	CN	sample.		This	is	interesting	because	it	suggests	
that	there	is	no	observable	synergistic	effect	of	APOE	e4	and	Aβ	on	hippocampal	volume	in	CN	










dependent	on	p-tau	becoming	abnormal.	Together,	 these	results	suggest	 that	 the	APOE	e4	
driven	 hippocampal	 changes	 become	 most	 prominent	 in	 the	 later	 stages	 of	 AD	
pathophysiology,	with	MCI	and	AD	patients	becoming	most	affected.	CN	individuals	and	non-
demented	individuals	demonstrate	no	independent	APOE	e4	risk	on	hippocampal	volume.	The	











One	 explanation	 for	 this	 finding	 may	 be	 related	 to	 the	 dynamic	 and	 asynchronous	
neurobiological	 processes	 occurring	 during	 brain	 maturation	 in	 adolescence.	 For	 instance,	
neurobiological	 changes	 such	 as	 intracortical	 myelination,	 synaptic	 pruning,	 and	 dendritic	
arborisation	 usually	 optimize	 the	 brain	 for	 challenges	 ahead	 in	 adulthood.	 In	 cases	 of	
antagonistic	pleiotropy,	these	optimized	changes	may	actually	confer	beneficial	effects	during	
adolescent	development	and	early	adulthood,	at	the	expense	of	more	rapid	decline	in	older	
age	 [21].	 To	 investigate	 this	 phenomenon,	 I	 tested	 the	 effect	 of	 different	APOE	 groups	 on	




detrimental	 effect	on	 the	brain	may	be	 linked	 to	 the	pathological	 cascade	of	 events	 in	AD	
pathogenesis.	In	contrast,	it	is	also	possible	that	white-matter	(WM)	changes	could	precede	
grey	 matter	 alterations	 associated	 with	 APOE	 in	 adolescence.	 Deviations	 in	 optimised	
	 223	
neurobiological	 changes	 during	 adolescence	 could	 render	 key	 allocortical	 fibre	 pathways	
susceptible	to	vulnerabilities	in	the	WM	network.		
	
To	 investigate	 this	 potential	 phenomenon,	 in	 Chapter	 6,	 I	 compared	 the	 diffusion	
characteristics	of	WM	microstructure	 in	 relation	 to	 the	APOE	gene	 in	 the	diffusion	 imaging	
subset	 of	 14-yr	 old	 healthy	 adolescents.	 The	 results	 of	 the	 unbiased	 whole-brain	 analysis	
revealed	no	significant	differences,	across	all	diffusion	indices,	in	healthy	adolescents	in	APOE	





in	 brain	 volume	 [22].	 Moreover,	 studies	 in	 young	 adult	 APOE	 e4	 carriers	 show	 that	 brain	
structure	becomes	particularly	vulnerable	in	middle	and	old	age.	This	early	pretangle	phase	of	
tau	lesions,	though	protracted,	is	believed	to	begin	in	young	adulthood	[23,24].	However,	what	
is	 less	consistent	 is	whether	these	neuropathological	changes	associated	with	APOE	in	 later	
age	 are	 congruous	 with	 AD	 pathogenesis	 or	 simply	 constitute	 a	 non-pathological	 ageing	
process.		
	






heteromodal	 network	 of	 regions	 underlying	 significant	 hypometabolism	 and	 Aβ	 deposition	
[26].	The	posteromedial	cortex	(PMC),	a	region	consisting	of	the	precuneus,	posterior	cingulate	
cortex	(PCC)	and	retrosplenial	cortex	(RSC),	 is	a	cortical	hub	anchored	 in	the	DMN	that	has	






and	 ventral	 subdivisions	 that	 show	 a	 complex	 pattern	 of	 brain	 activity	 partially	 reflecting	




decline	of	 the	RSC	with	MTL	networks	supporting	memory	and	cognition,	and	 (iii)	a	 frontal	
hyperconnectivity	 burden	 of	 the	 ventral	 PCC	 with	 the	 VMPFC	 region,	 compared	 to	 CN	
individuals.		
	
To	 investigate	 whether	 a	 similar	 pattern	 of	 PMC	 systems-level	 pathophysiology	 could	 be	




























they	provide	 the	potential	 to	estimate	antecedent	changes	 in	prodromal	MCI	patients	 that	
might	 imminently	 convert	 to	 AD.	 Perhaps	 the	 best	 ways	 to	 track	 brain	 changes	 across	
structures	 over	 time	 may	 be	 to	 devise	 a	 combination	 of	 longitudinal	 and	 cross-sectional	











replicated	 in	 more	 representative	 and	 ethnically	 diverse	 prospective	 cohorts	 for	 robust	
validation.		
	





[31].	 Consequently,	 this	 atlas	was	 only	 sufficient	 to	 produce	 a	 coarse	 segmentation	 of	 the	













in	 the	delineation	protocol.	 Recently,	 a	 novel	Bayesian	 approach	has	 further	developed	an	
automated	method	allowing	for	the	segmentation	of	hippocampal	subfields	across	multiple	




in	 multivariate	 computational	 algorithms	 for	 predicting	 the	 progression	 to	 AD	 in	 MCI	
individuals.	Despite	the	models	showing	good	prognostic	ability	in	detecting	AD	in	MCI	patients	
that	 eventually	 converted	 to	 AD	 at	 follow-up,	 model	 performance	 for	 MCI	 subjects	 that	
remained	clinically	stable	was	poor.	According	to	previous	studies	this	 is	a	well	 -recognised	
problem	[8,12,34].	MCI	subjects	represent	a	heterogeneous	population	of	individuals	that	will	








by	 evidence	 suggesting	 that	 the	 normal	 healthy	 ageing	 brain	 is	 also	 characterised	 by	 the	
presence	of	cortical	atrophy,	albeit	of	a	non-AD,	non-pathological	origin	[35].	Contrary	to	this	
view,	others	have	suggested	that	the	presence	of	cortical	decline	is	not	a	feature	concomitant	
of	 normal	 healthy	 ageing	 but	 rather	 a	 cause	 of	 preclinical	 cognitive	 pathology	 [36].	 Thus,	
conceptualising	 the	 temporal	 gap	 between	 latent	 pathology	 in	 a	 yet	 undetected	
neurodegenerative	disease	such	as	AD,	and	that	of	a	presumable	normal	ageing	process	has	
































address	 this	 issue	 by	 exploring	 RSC	 function	 using	 high-field	 7T	 systems	 or	 investigating	






work	 in	 an	 independent	 rsfMRI	 dataset	 to	 acquire	 a	 better	 conceptualisation	 of	 network	
failures	in	AD.		
	
As	prevailing	evidence	accumulates	 to	 suggest	 that	different	neuroimaging	modalities	 can	
detect	 pathological	 changes	 years	 before	 AD	 manifests	 clinically	 there	 has	 also	 been	 an	
increased	 interest	 to	measure	 clinical	 usefulness.	 Currently,	 FDG-PET	 is	 a	well-established	
method	 for	 the	 prognosis	 of	 dementia	 in	 MCI	 patients	 and	 structural	 MRI	 provides	 a	
quantitative	 approach	 for	 staging	 of	 neuronal	 loss	 [41].	 Studies	 show	 that	measurements	
from	 hippocampal	 volumetry	 can	 achieve	 accuracy	 rates	 of	 up	 to	 80%	 in	 predicting	 the	
progression	of	dementia	 in	MCI	patients	with	over	3	years	of	 follow-up	 [42].	However,	 to	
predict	clinical	progression	at	an	individual	level,	neuroimaging	biomarkers	as	diagnostic	tools	
must	have	a	sensitivity	well	over	90%	and	a	specificity	near	100%,	be	reliable,	easily	accessible	







using	 fully	 automated	 atlas-based	 hippocampal	 volumetry	 in	 a	 secondary	 care	 memory	
clinical	 outpatient	 sample	 demonstrating	 a	 promising	 84%	 accuracy	 in	 detecting	 AD	 [43].	
Despite	this,	several	non-medical	factors	influence	the	use	of	imaging	techniques	for	routine	
clinical	application.	For	instance,	economic	factors	relating	to	the	high	cost	of	new	technology	
in	 neuroimaging,	 such	 as	 combined	MRI/PET	 systems	 and	 high-field	 innovations	 currently	
limit	 broad	 application.	 Moreover,	 regulatory	 requirements	 for	 standardisation	 and	
certification	of	imaging	techniques	means	accurate	harmonized	reference	standards	and	cut-






pose	 for	 routine	 clinical	 implementation	 and	 use	 as	 enrichment	 tools	 for	 clinical	 trials.	 A	










Standardisation	 of	 methods	 still	 remains	 a	 significant	 challenge,	 although	 international	










the	 in-vivo	 assessment	 of	 cortical	 atrophy	 using	 structural	 MRI	 techniques,	 studying	 the	





novel	 CSF	 candidates	 of	 inflammation,	 microglial	 activity,	 and	 synaptic	 function	 can	
complement	regional	MRI	measures	of	brain	atrophy	for	AD	classification	and	MCI	prediction.		
	
Building	on	previous	neuroimaging	APOE	studies,	 I	have	explored	 the	 relationship	between	
APOE	and	brain	structure	across	the	AD	clinical	spectrum,	and	healthy	young	adolescents	with	
differential	 APOE	 risk.	 These	 comparisons	 provide	 strong	 support	 to	 suggest	 hippocampal	
atrophy	is	moderated	by	APOE	e4	in	AD	patients	and	MCI	patients.	However,	I	was	unable	to	
show	that	(1)	neuroanatomic	mechanisms	of	APOE	e4	on	the	hippocampus	were	present	in	
healthy	 older	 non-demented	 individual	 and	 (2)	 APOE	 e4	 shares	 a	 neurodevelopmental	






pathogenesis.	 Given	 the	 complexity	 and	 sometimes	 overlapping	 characteristics	 of	 AD	
pathophysiology,	it	is	unlikely	that	a	single	biomarker	would	be	able	to	provide	the	diagnostic	
certainty	 required	 for	 the	 earlier	 detection	 of	 AD.	 To	 gain	 a	 better	 insight	 into	 dynamic	
neuroimaging	 biomarker	 trajectories,	 we	 will	 require	 a	 wider	 use	 in	 the	 arsenal	 of	 AD	
biomarkers	to	study	of	the	cognitively	intact	elderly.	It	has	become	clear	that	almost	20-30%	
of	cognitively	normal	persons	show	abnormal	patterns	of	Aβ	deposition	on	PET	scans	 [44].	
Since,	 longitudinal	 studies	 of	 reliable	 biomarkers	 of	 Aβ	 pathology	 have	 shown	 promise	 in	
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and	 preventive	 options	 are	 available	 for	 patients	 worldwide.	 This	 raises	 several	 ethical	
questions	with	 the	 potential	 benefits	 of	 biomarker-driven	 early	 diagnosis	weighted	 against	
possible	disadvantages.	Currently,	there	are	very	few	arguments	favouring	early	diagnosis	for	
prevention,	due	to	the	lack	of	effective	disease-modifying	therapy.	However,	a	possible	benefit	
of	 early	 diagnosis	 is	 that	 it	 may	 enable	 early	 decision	 making	 and	 could	 facilitate	 the	
introduction	of	 disease	management	 tools	 to	help	 assist	 patients	 to	 cope	with	progressive	
decline.	The	ethical	implications	of	a	false	positive	diagnosis	resulting	in	treatment	and	leading	
to	a	harmful	side	effect	should	also	be	considered.	In	such	a	case,	it	would	represent	a	serious	
infringe	 on	 the	 basic	 medical	 ethics	 principle	 of	 nonmaleficence.	 	 Therefore,	 the	 positive	
effects	of	treatment	must	be	considered	against	side	effects,	as	well	as	treatment	cost,	when	












drive	 clinical	 progression.	Understanding	which	 protein	 serves	 its	 role	 as	 a	 ‘trigger’	 driving	
neurodegeneration	 and	 the	 ‘bullet’	 for	 eventual	 cognitive	 decline	 is	 highly	 relevant	 for	
developing	 and	 testing	 effective	 future	 therapies.	 Several	 avenues	 of	 future	 biomarker	
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exhibit	 the	 desired	 binding	 affinity	 to	 tau	 aggregates,	 high	 permeability	 of	 the	 blood-brain	
barrier,	and	other	tracer	kinetics	to	accurately	reflect	the	spatial	pattern	of	tau	deposition	in	
the	 brain.	 However,	 18F-AV-1451,	 a	 benzimidazole	 pyrimidine	 derivative,	 is	 in	 Phase	 2	













Since	blood	 is	more	accessible	 than	 routine	CSF	 collection,	 for	which	a	 lumbar	puncture	 is	
needed,	 blood-based	 biomarkers	 are	 desirable	 as	 a	 potential	 high-throughput	 frontline	







markers	of	AD	pathology	 [58].	 	Given	 the	 complexity	of	AD	pathogenesis,	 it	 seems	 that	an	











data	 can	 potentially	 advance	 neurodegenerative	 research	 and	 drug	 development.	 Recent	
initiatives	 proposing	 the	 use	 of	 integrative	 predictive	 platforms	 to	 create	 a	 systems-based	
understanding	of	AD	could	help	build	new	 treatment	paradigms	where	potential	new	drug	









The	UK	biobank	 (ww.ukbiobank.ac.uk)	 represents	a	major	national	and	 international	health	
resource	with	the	aim	of	improving	the	diagnosis	and	prevention	of	several	illnesses,	including	
various	forms	of	dementia.	 It	 is	also	a	rich	resource	for	extensive	neuroimaging	data	which	
could	 be	 used	 to	 characterise	 the	 structural	 vulnerabilities	 of	 the	 brain	 in	 normal	 ageing.	
Elucidating	the	mechanisms	of	non-pathological	brain	changes	may	help	inform	on	why	the	
ageing	brain	is	so	much	more	susceptible	to	AD	than	is	the	younger	brain.	For	instance,	the	





The	 Human	 Connectome	 Project	 consortium	 led	 by	 Washington	 University,	 University	 of	
Minnesota,	 and	 Oxford	 University	 is	 undertaking	 a	 systematic	 effort	 to	 map	 macroscopic	
human	brain	circuits	and	their	relationship	to	behaviour	in	a	large	population	of	healthy	adults	
[64].	 Refining	methods	 for	 data	 acquisition	 and	 preprocessing	will	 enable	 the	 analysis	 and	
visualisation	 of	 brain	 structure,	 function,	 and	 connectivity	 with	 exceptional	 high	 quality.		
Advances	 in	 diffusion	 MRI	 acquisition	 techniques,	 fibre	 orientation	 estimation	 and	
tractography	will	enable	a	higher	quality	quantification	of	structural	brain	connectivity	[65].		
	
Another	 key	 objective	 for	 HCP	 is	 to	 generate	 a	 detailed	 in-vivo	 mapping	 of	 functional	











In	 conclusion,	 the	 studies	 in	 this	 thesis	 suggest	 that	 neuroimaging	 biomarkers	 of	 brain	
structure	 and	 function	 demonstrate	 sensitivity	 in	 detecting	 AD	 pathology,	 even	 in	 the	
prodromal	 MCI	 stages	 of	 development.	 The	 first	 study	 of	 this	 thesis	 demonstrates	 that	
automated	hippocampal	 subfield	measurements	 provide	 increased	 sensitivity	 for	 detecting	










events	 underlying	 the	 complex	 aetiology	 of	 AD	 pathogenesis.	 More	 detailed	 and	 refined	
neuroimaging	 methods	 alongside	 an	 extensive	 pool	 of	 multimodal	 biomarker	 data	 will	
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Table	 S3:	 CSF	 Proteins	 from	 the	multiplex	 panel	 associated	 with	 neuroimaging	markers	 of	
atrophy,	SPARE-AD	score,	and	CSF	biomarkers	of	AD	
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*Bold	indicates	statistically	significant	effect	
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APPENDIX	1:	SUPPLEMENTARY	ONLINE	MATERIALS	FROM	CHAPTER	4	
	
Each	cohort	that	was	included	in	the	AD	and	normal	ageing	dataset	(n=1781)	is	shown	below	
with	demographic	characteristics	and	APOE	hippocampal	comparisons.		
	
Table	S1:	Demographic	Characteristics	and	Hippocampal	volumes	of	the	ADNI	cohort	(n=779)	
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Table	S2:	Demographic	Characteristics	and	Hippocampal	volumes	of	the	AIBL	cohort	(n=228)	
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Table	S3:	Demographic	Characteristics	and	Hippocampal	volumes	of	the	AddNeuroMed	cohort	
(n=303)	
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Table	S4:	Demographic	Characteristics	and	Hippocampal	volumes	of	the	BRC-AD	Cohort	(n=89)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
	
	
